



## Prior Authorization requirement changes - effective 6/1/2025:

On **6/1/2025**, prior authorization (PA) requirements will change for a large number of new CPT/HCPCS code(s) which became effective between 1/1/2024 and 1/1/2025. All of the new medical code(s) listed in the chart below will require prior authorization by SCAN as of 6/1/2025 for members in the following plans:

### **Arizona IPA Groups**

I1211 SCAN Medical Group  
I1212 SCAN Contracted Network  
I1227 SCAN Contracted Network  
I1238 CenterWell Senior Primary Care  
I1239 Evernorth Care Group  
I1241 SCAN Contracted Network  
I1264 SCAN Contracted Network  
I1273 SCAN Medical Group  
I1295 SCAN Contracted Network  
I1296 SCAN Contracted Network  
I1316 Oak Street Health Physicians Group of Arizona  
I1327 SCAN Contracted Network  
I1332 IntraCare Health Center  
I1355 SCAN Contracted Network  
I1359 Optum Health Network  
I1361 Village Medical  
I1363 SCAN Contracted Network  
I1363 Phoenix Physicians IPA  
I1364 SCAN Contracted Network

### **New Mexico IPA Groups**

I1231 SCAN Contracted Network  
I1266 SCAN Contracted Network  
I1298 SCAN Contracted Network  
I1315 Lovelace Medical Group  
I1318 Oak Street Health Physicians Group of New Mexico  
I1325 SCAN Contracted Network  
I1326 SCAN Contracted Network

### **California IPA Groups**

I1180 SCAN Medical Group  
I1181 SCAN Medical Group  
I1257 UCI University Phys & Surg  
I1258 SCAN Contracted Network  
I1263 SCAN Contracted Network  
I1289 SCAN Contracted Network  
I1290 SCAN Contracted Network  
I1291 SCAN Contracted Network  
I1294 SCAN Contracted Network  
I1328 SCAN Contracted Network

### **Texas IPA Groups**

I1221 SCAN Contracted Network  
I1293 SCAN Contracted Network  
I1300 SCAN Contracted Network  
I1302 Houston Physicians IPA  
I1306 Renaissance Physicians Organization  
I1309 Heritage Physicians Networks  
I1312 ViCare Health IPA  
I1317 Oak Street Health Physicians Group of Texas  
I1320 SCAN Contracted Network  
I1321 SCAN Contracted Network  
I1322 SCAN Contracted Network  
I1323 SCAN Contracted Network  
I1324 SCAN Contracted Network

Centers for Medicare & Medicaid Services (CMS) guidelines, Federal and state law, and state contract language may take precedence over these precertification rules and must be considered first when determining coverage. For additional information, please reference: [Medical Policy Guidance \(scanhealthplan.com\)](https://scanhealthplan.com).

Refer to the member's insurance card to confirm the plan in which member is enrolled. For members NOT enrolled in the plans and service areas listed above, please contact the member's assigned medical group for applicable prior authorization requirements.

### **Non-compliance with new requirements may result in denied claims.**

Not all Prior Authorization requirements are listed here. Detailed PA requirements are available to providers at [Provider Portal Information and Resources - SCAN Health Plan](#). Providers may also call the number on the back of their patient's member ID card for assistance with PA requirements.



## STATEMENT ON NEW CPT & HCPCS CODES:

Beginning in 2025, SCAN's default stance is that all newly defined CPT and HCPCS codes will be added to the Prior Authorization list upon publication by CMS, which typically occurs on January 1<sup>st</sup>.

All codes on the PA List will be evaluated routinely for exclusion from the PA List.

Changes will be posted to the SCAN Website in advance of effective date.

### Additions to SCAN Prior Authorization List - Effective 6/1/25

#### Newly implemented CPT/HCPCS codes (1/1/24 – 1/1/25)

ADDED DATE	CODE	DESCRIPTION
Jan-25	<b>15011</b>	Harvest of skin for skin cell suspension autograft; first 25 sq cm or less
Jan-25	<b>15012</b>	Harvest of skin for skin cell suspension autograft; each additional 25 sq cm or part thereof (List separately in addition to code for primary procedure)
Jan-25	<b>15013</b>	Preparation of skin cell suspension autograft, requiring enzymatic processing, manual mechanical disaggregation of skin cells, and filtration; first 25 sq cm or less of harvested skin
Jan-25	<b>15014</b>	Preparation of skin cell suspension autograft, requiring enzymatic processing, manual mechanical disaggregation of skin cells, and filtration; each additional 25 sq cm of harvested skin or part thereof (List separately in addition to code for primary procedure)
Jan-25	<b>15015</b>	Application of skin cell suspension autograft to wound and donor sites, including application of primary dressing, trunk, arms, legs; first 480 sq cm or less
Jan-25	<b>15016</b>	Application of skin cell suspension autograft to wound and donor sites, including application of primary dressing, trunk, arms, legs; each additional 480 sq cm or part thereof (List separately in addition to code for primary procedure)
Jan-25	<b>15017</b>	Application of skin cell suspension autograft to wound and donor sites, including application of primary dressing, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; first 480 sq cm or less
Jan-25	<b>15018</b>	Application of skin cell suspension autograft to wound and donor sites, including application of primary dressing, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; each additional 480 sq cm or part thereof (List separately in addition to code for primary procedure)
Jan-25	<b>25448</b>	Arthroplasty, intercarpal or carpometacarpal joints; suspension, including transfer or transplant of tendon, with interposition, when performed
Jan-25	<b>38225</b>	Chimeric antigen receptor T-cell (CAR-T) therapy; harvesting of blood-derived T lymphocytes for development of genetically modified autologous CAR-T cells, per day
Jan-25	<b>38226</b>	Chimeric antigen receptor T-cell (CAR-T) therapy; preparation of blood-derived T lymphocytes for transportation (eg, cryopreservation, storage)
Jan-25	<b>38227</b>	Chimeric antigen receptor T-cell (CAR-T) therapy; receipt and preparation of CAR-T cells for administration
Jan-25	<b>38228</b>	Chimeric antigen receptor T-cell (CAR-T) therapy; CAR-T cell administration, autologous
Jan-25	<b>49186</b>	Excision or destruction, open, intra-abdominal (ie, peritoneal, mesenteric, retroperitoneal), primary or secondary tumor(s) or cyst(s), sum of the maximum length of tumor(s) or cyst(s); 5 cm or less
Jan-25	<b>49187</b>	Excision or destruction, open, intra-abdominal (ie, peritoneal, mesenteric, retroperitoneal), primary or secondary tumor(s) or cyst(s), sum of the maximum length of tumor(s) or cyst(s); 5.1 to 10 cm
Jan-25	<b>49188</b>	Excision or destruction, open, intra-abdominal (ie, peritoneal, mesenteric, retroperitoneal), primary or secondary tumor(s) or cyst(s), sum of the maximum length of tumor(s) or cyst(s); 10.1 to 20 cm
Jan-25	<b>49189</b>	Excision or destruction, open, intra-abdominal (ie, peritoneal, mesenteric, retroperitoneal), primary or secondary tumor(s) or cyst(s), sum of the maximum length of tumor(s) or cyst(s); 20.1 to 30 cm
Jan-25	<b>49190</b>	Excision or destruction, open, intra-abdominal (ie, peritoneal, mesenteric, retroperitoneal), primary or secondary tumor(s) or cyst(s), sum of the maximum length of tumor(s) or cyst(s); greater than 30 cm
Jan-25	<b>51721</b>	Insertion of transurethral ablation transducer for delivery of thermal ultrasound for prostate tissue ablation, including suprapubic tube placement during the same session and placement of an endorectal cooling device, when performed
Jan-25	<b>53865</b>	Cystourethroscopy with insertion of temporary device for ischemic remodeling (ie, pressure necrosis) of bladder neck and prostate
Jan-25	<b>53866</b>	Catheterization with removal of temporary device for ischemic remodeling (ie, pressure necrosis) of bladder neck and prostate
Jan-25	<b>55881</b>	Ablation of prostate tissue, transurethral, using thermal ultrasound, including magnetic resonance imaging guidance for, and monitoring of, tissue ablation;
Jan-25	<b>55882</b>	Ablation of prostate tissue, transurethral, using thermal ultrasound, including magnetic resonance imaging guidance for, and monitoring of, tissue ablation; with insertion of transurethral ultrasound transducer for delivery of thermal ultrasound, including suprapubic tube placement and placement of an endorectal cooling device, when performed
Jan-25	<b>60660</b>	Ablation of 1 or more thyroid nodule(s), one lobe or the isthmus, percutaneous, including imaging guidance, radiofrequency
Jan-25	<b>60661</b>	Ablation of 1 or more thyroid nodule(s), additional lobe, percutaneous, including imaging guidance, radiofrequency (List separately in addition to code for primary procedure)
Jan-25	<b>61715</b>	Magnetic resonance image guided high intensity focused ultrasound (MRgFUS), stereotactic ablation of target, intracranial, including stereotactic navigation and frame placement, when performed
Jan-25	<b>64466</b>	Thoracic fascial plane block, unilateral; by injection(s), including imaging guidance, when performed

Jan-25	<b>64467</b>	Thoracic fascial plane block, unilateral; by continuous infusion(s), including imaging guidance, when performed
Jan-25	<b>64468</b>	Thoracic fascial plane block, bilateral; by injection(s), including imaging guidance, when performed
Jan-25	<b>64469</b>	Thoracic fascial plane block, bilateral; by continuous infusion(s), including imaging guidance, when performed
Jan-25	<b>64473</b>	Lower extremity fascial plane block, unilateral; by injection(s), including imaging guidance, when performed
Jan-25	<b>64474</b>	Lower extremity fascial plane block, unilateral; by continuous infusion(s), including imaging guidance, when performed
Jan-25	<b>66683</b>	Implantation of iris prosthesis, including suture fixation and repair or removal of iris, when performed
Jan-25	<b>76014</b>	MR safety implant and/or foreign body assessment by trained clinical staff, including identification and verification of implant components from appropriate sources (eg, surgical reports, imaging reports, medical device databases, device vendors, review of prior imaging), analyzing current MR conditional status of individual components and systems, and consulting published professional guidance with written report; initial 15 minutes
Jan-25	<b>76015</b>	MR safety implant and/or foreign body assessment by trained clinical staff, including identification and verification of implant components from appropriate sources (eg, surgical reports, imaging reports, medical device databases, device vendors, review of prior imaging), analyzing current MR conditional status of individual components and systems, and consulting published professional guidance with written report; each additional 30 minutes (List separately in addition to code for primary procedure)
Jan-25	<b>76016</b>	MR safety determination by a physician or other qualified health care professional responsible for the safety of the MR procedure, including review of implant MR conditions for indicated MR examination, analysis of risk vs clinical benefit of performing MR examination, and determination of MR equipment, accessory equipment, and expertise required to perform examination, with written report
Jan-25	<b>76017</b>	MR safety medical physics examination customization, planning and performance monitoring by medical physicist or MR safety expert, with review and analysis by physician or other qualified health care professional to prioritize and select views and imaging sequences, to tailor MR acquisition specific to restrictive requirements or artifacts associated with MR conditional implants or to mitigate risk of non-conditional implants or foreign bodies, with written report
Jan-25	<b>76018</b>	MR safety implant electronics preparation under supervision of physician or other qualified health care professional, including MR-specific programming of pulse generator and/or transmitter to verify device integrity, protection of device internal circuitry from MR electromagnetic fields, and protection of patient from risks of unintended stimulation or heating while in the MR room, with written report
Jan-25	<b>76019</b>	MR safety implant positioning and/or immobilization under supervision of physician or other qualified health care professional, including application of physical protections to secure implanted medical device from MR-induced translational or vibrational forces, magnetically induced functional changes, and/or prevention of radiofrequency burns from inadvertent tissue contact while in the MR room, with written report
Jan-25	<b>81195</b>	Cytogenomic (genome-wide) analysis, hematologic malignancy, structural variants and copy number variants, optical genome mapping (OGM)
Jan-25	<b>81515</b>	Infectious disease, bacterial vaginosis and vaginitis, real-time PCR amplification of DNA markers for Atopobium vaginae, Atopobium species, Megasphaera type 1, and Bacterial Vaginosis Associated Bacteria-2 (BVAB-2), utilizing vaginal-fluid specimens, algorithm reported as positive or negative for high likelihood of bacterial vaginosis, includes separate detection of Trichomonas vaginalis and Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis), Candida glabrata/Candida krusei, when reported
Jan-25	<b>81558</b>	Transplantation medicine (allograft rejection, kidney), mRNA, gene expression profiling by quantitative polymerase chain reaction (qPCR) of 139 genes, utilizing whole blood, algorithm reported as a binary categorization as transplant excellence, which indicates immune quiescence, or not transplant excellence, indicating subclinical rejection
Jan-25	<b>82233</b>	Beta-amyloid; 1-40 (Aβ40)
Jan-25	<b>82234</b>	Beta-amyloid; 1-42 (Aβ42)
Jan-25	<b>83884</b>	Neurofilament light chain (NfL)
Jan-25	<b>84393</b>	Tau, phosphorylated (eg, pTau 181, pTau 217), each
Jan-25	<b>84394</b>	Tau, total (tTau)
Jan-25	<b>86581</b>	Streptococcus pneumoniae antibody (IgG), serotypes, multiplex immunoassay, quantitative
Jan-25	<b>87513</b>	Infectious agent detection by nucleic acid (DNA or RNA); Helicobacter pylori (H. pylori), clarithromycin resistance, amplified probe technique
Jan-25	<b>87564</b>	Infectious agent detection by nucleic acid (DNA or RNA); Mycobacterium tuberculosis, rifampin resistance, amplified probe technique
Jan-25	<b>87594</b>	Infectious agent detection by nucleic acid (DNA or RNA); Pneumocystis jirovecii, amplified probe technique
Jan-25	<b>87626</b>	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), separately reported high-risk types (eg, 16, 18, 31, 45, 51, 52) and high-risk pooled result(s)
Jan-25	<b>90593</b>	Chikungunya virus vaccine, recombinant, for intramuscular use
Oct-24	<b>90624</b>	Meningococcal pentavalent vaccine, Men B-4C recombinant proteins and outer membrane vesicle and conjugated Men A, C, W, Y-diphtheria toxoid carrier, for intramuscular use
Jul-24	<b>90637</b>	Influenza virus vaccine, quadrivalent (qIVR), mRNA; 30 mcg/0.5 mL dosage, for intramuscular use
Jul-24	<b>90638</b>	Influenza virus vaccine, quadrivalent (qIVR), mRNA; 60 mcg/0.5 mL dosage, for intramuscular use
Jul-24	<b>90684</b>	Pneumococcal conjugate vaccine, 21 valent (PCV21), for intramuscular use
Jul-24	<b>90695</b>	Influenza virus vaccine, H5N8, derived from cell cultures, adjuvanted, for intramuscular use
Jan-25	<b>92137</b>	Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina, including OCT angiography
Jan-25	<b>93896</b>	Vasoreactivity study performed with transcranial Doppler study of intracranial arteries, complete (List separately in addition to code for primary procedure)
Jan-25	<b>93897</b>	Emboli detection without intravenous microbubble injection performed with transcranial Doppler study of intracranial arteries, complete (List separately in addition to code for primary procedure)

Jan-25	<b>93898</b>	Venous-arterial shunt detection with intravenous microbubble injection performed with transcranial Doppler study of intracranial arteries, complete (List separately in addition to code for primary procedure)
Jan-25	<b>96041</b>	Medical genetics and genetic counseling services, each 30 minutes of total time provided by the genetic counselor on the date of the encounter
Jan-25	<b>98000</b>	Synchronous audio-video visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and straightforward medical decision making. When using total time on the date of the encounter for code selection, 15 minutes must be met or exceeded.
Jan-25	<b>98001</b>	Synchronous audio-video visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and low medical decision making. When using total time on the date of the encounter for code selection, 30 minutes must be met or exceeded.
Jan-25	<b>98002</b>	Synchronous audio-video visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and moderate medical decision making. When using total time on the date of the encounter for code selection, 45 minutes must be met or exceeded.
Jan-25	<b>98003</b>	Synchronous audio-video visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and high medical decision making. When using total time on the date of the encounter for code selection, 60 minutes must be met or exceeded.
Jan-25	<b>98004</b>	Synchronous audio-video visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and straightforward medical decision making. When using total time on the date of the encounter for code selection, 10 minutes must be met or exceeded.
Jan-25	<b>98005</b>	Synchronous audio-video visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and low medical decision making. When using total time on the date of the encounter for code selection, 20 minutes must be met or exceeded.
Jan-25	<b>98006</b>	Synchronous audio-video visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and moderate medical decision making. When using total time on the date of the encounter for code selection, 30 minutes must be met or exceeded.
Jan-25	<b>98007</b>	Synchronous audio-video visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and high medical decision making. When using total time on the date of the encounter for code selection, 40 minutes must be met or exceeded.
Jan-25	<b>98008</b>	Synchronous audio-only visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination, straightforward medical decision making, and more than 10 minutes of medical discussion. When using total time on the date of the encounter for code selection, 15 minutes must be met or exceeded.
Jan-25	<b>98009</b>	Synchronous audio-only visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination, low medical decision making, and more than 10 minutes of medical discussion. When using total time on the date of the encounter for code selection, 30 minutes must be met or exceeded.
Jan-25	<b>98010</b>	Synchronous audio-only visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination, moderate medical decision making, and more than 10 minutes of medical discussion. When using total time on the date of the encounter for code selection, 45 minutes must be met or exceeded.
Jan-25	<b>98011</b>	Synchronous audio-only visit for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination, high medical decision making, and more than 10 minutes of medical discussion. When using total time on the date of the encounter for code selection, 60 minutes must be met or exceeded.
Jan-25	<b>98012</b>	Synchronous audio-only visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination, straightforward medical decision making, and more than 10 minutes of medical discussion. When using total time on the date of the encounter for code selection, 10 minutes must be exceeded.
Jan-25	<b>98013</b>	Synchronous audio-only visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination, low medical decision making, and more than 10 minutes of medical discussion. When using total time on the date of the encounter for code selection, 20 minutes must be met or exceeded.
Jan-25	<b>98014</b>	Synchronous audio-only visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination, moderate medical decision making, and more than 10 minutes of medical discussion. When using total time on the date of the encounter for code selection, 30 minutes must be met or exceeded.
Jan-25	<b>98015</b>	Synchronous audio-only visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination, high medical decision making, and more than 10 minutes of medical discussion. When using total time on the date of the encounter for code selection, 40 minutes must be met or exceeded.
Jan-25	<b>98016</b>	Brief communication technology-based service (eg, virtual check-in) by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related evaluation and management service provided within the previous 7 days nor leading to an evaluation and management service or procedure within the next 24 hours or soonest available appointment, 5-10 minutes of medical discussion.
Jul-24	<b>0020M</b>	Oncology (central nervous system), analysis of 30000 DNA methylation loci by methylation array, utilizing DNA extracted from tumor tissue, diagnostic algorithm reported as probability of matching a reference tumor subclass
Jan-24	<b>0420U</b>	Oncology (urothelial), mRNA expression profiling by real-time quantitative PCR of MDK, HOXA13, CDC2, IGFBP5, and CXCR2 in combination with droplet digital PCR (ddPCR) analysis of 6 single-nucleotide polymorphisms (SNPs) genes TERT and FGFR3, urine, algorithm reported as a risk score for urothelial carcinoma
Jan-24	<b>0421U</b>	Oncology (colorectal) screening, quantitative real-time target and signal amplification of 8 RNA markers (GAPDH, SMAD4, ACY1, AREG, CDH1, KRAS, TNFRSF10B, EGLN2) and fecal hemoglobin, algorithm reported as a positive or negative for colorectal cancer risk
Jan-24	<b>0422U</b>	Oncology (pan-solid tumor), analysis of DNA biomarker response to anti-cancer therapy using cell-free circulating DNA, biomarker comparison to a previous baseline pre-treatment cell-free circulating DNA analysis using next-generation sequencing, algorithm reported as a quantitative change from baseline, including specific alterations, if appropriate
Jan-24	<b>0423U</b>	Psychiatry (eg, depression, anxiety), genomic analysis panel, including variant analysis of 26 genes, buccal swab, report including metabolizer status and risk of drug toxicity by condition



Jan-24	<b>0424U</b>	Oncology (prostate), exosome-based analysis of 53 small noncoding RNAs (sncRNAs) by quantitative reverse transcription polymerase chain reaction (RT-qPCR), urine, reported as no molecular evidence, low-, moderate- or elevated-risk of prostate cancer
Jan-24	<b>0425U</b>	Genome (eg, unexplained constitutional or heritable disorder or syndrome), rapid sequence analysis, each comparator genome (eg, parents, siblings)
Jan-24	<b>0426U</b>	Genome (eg, unexplained constitutional or heritable disorder or syndrome), ultra-rapid sequence analysis
Jan-24	<b>0427U</b>	Monocyte distribution width, whole blood (List separately in addition to code for primary procedure)
Jan-24	<b>0429U</b>	Human papillomavirus (HPV), oropharyngeal swab, 14 high-risk types (ie, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68)
Jan-24	<b>0430U</b>	Gastroenterology, malabsorption evaluation of alpha-1-antitrypsin, calprotectin, pancreatic elastase and reducing substances, feces, quantitative
Jan-24	<b>0431U</b>	Glycine receptor alpha1 IgG, serum or cerebrospinal fluid (CSF), live cell-binding assay (LCBA), qualitative
Jan-24	<b>0432U</b>	Kelch-like protein 11 (KLHL11) antibody, serum or cerebrospinal fluid (CSF), cell-binding assay, qualitative
Jan-24	<b>0433U</b>	Oncology (prostate), 5 DNA regulatory markers by quantitative PCR, whole blood, algorithm, including prostate-specific antigen, reported as likelihood of cancer
Jan-24	<b>0434U</b>	Drug metabolism (adverse drug reactions and drug response), genomic analysis panel, variant analysis of 25 genes with reported phenotypes
Jan-24	<b>0435U</b>	Oncology, chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), from cultured CSCs and primary tumor cells, categorical drug response reported based on cytotoxicity percentage observed, minimum of 14 drugs or drug combinations
Jan-24	<b>0436U</b>	Oncology (lung), plasma analysis of 388 proteins, using aptamer-based proteomics technology, predictive algorithm reported as clinical benefit from immune checkpoint inhibitor therapy
Jan-24	<b>0437U</b>	Psychiatry (anxiety disorders), mRNA, gene expression profiling by RNA sequencing of 15 biomarkers, whole blood, algorithm reported as predictive risk score
Jan-24	<b>0438U</b>	Drug metabolism (adverse drug reactions and drug response), buccal specimen, gene-drug interactions, variant analysis of 33 genes, including deletion/duplication analysis of CYP2D6, including reported phenotypes and impacted gene-drug interactions
Apr-24	<b>0439U</b>	Cardiology (coronary heart disease [CHD]), DNA, analysis of 5 single-nucleotide polymorphisms (SNPs) (rs11716050 [LOC105376934], rs6560711 [WDR37], rs3735222 [SCIN/LOC107986769], rs6820447 [intergenic], and rs9638144 [ESYT2]) and 3 DNA methylation markers (cg00300879 [transcription start site [TSS200] of CNKSR1], cg09552548 [intergenic], and cg14789911 [body of SPATC1L]), qPCR and digital PCR, whole blood, algorithm reported as a 4-tiered risk score for a 3-year risk of symptomatic CHD
Apr-24	<b>0440U</b>	Cardiology (coronary heart disease [CHD]), DNA, analysis of 10 single-nucleotide polymorphisms (SNPs) (rs710987 [LINC010019], rs1333048 [CDKN2B-AS1], rs12129789 [KCND3], rs942317 [KTN1-AS1], rs1441433 [PPP3CA], rs2869675 [PREX1], rs4639796 [ZBTB41], rs4376434 [LINC00972], rs12714414 [TMEM18], and rs7585056 [TMEM18]) and 6 DNA methylation markers (cg03725309 [SARS1], cg12586707 [CXCL1], cg04988978 [MPO], cg17901584 [DHCR24-DT], cg21161138 [AHRR], and cg12655112 [EHD4]), qPCR and digital PCR, whole blood, algorithm reported as detected or not detected for CHD
Apr-24	<b>0441U</b>	Infectious disease (bacterial, fungal, or viral infection), semiquantitative biomechanical assessment (via deformability cytometry), whole blood, with algorithmic analysis and result reported as an index
Apr-24	<b>0442U</b>	Infectious disease (respiratory infection), Myxovirus resistance protein A (MxA) and C-reactive protein (CRP), fingerstick whole blood specimen, each biomarker reported as present or absent
Apr-24	<b>0443U</b>	Neurofilament light chain (NfL), ultra-sensitive immunoassay, serum or cerebrospinal fluid
Apr-24	<b>0444U</b>	Oncology (solid organ neoplasia), targeted genomic sequence analysis panel of 361 genes, interrogation for gene fusions, translocations, or other rearrangements, using DNA from formalin-fixed paraffin-embedded (FFPE) tumor tissue, report of clinically significant variant(s)
Apr-24	<b>0445U</b>	B-amyloid (Abeta42) and phospho tau (181P) (pTau181), electrochemiluminescent immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology
Apr-24	<b>0446U</b>	Autoimmune diseases (systemic lupus erythematosus [SLE]), analysis of 10 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic risk score for current disease activity
Apr-24	<b>0447U</b>	Autoimmune diseases (systemic lupus erythematosus [SLE]), analysis of 11 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic prognostic risk score for developing a clinical flare
Apr-24	<b>0449U</b>	Carrier screening for severe inherited conditions (eg, cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies [including sickle cell disease], alpha thalassemia), regardless of race or self-identified ancestry, genomic sequence analysis panel, must include analysis of 5 genes (CFTR, SMN1, HBB, HBA1, HBA2)
Jul-24	<b>0450U</b>	Oncology (multiple myeloma), liquid chromatography with tandem mass spectrometry (LC-MS/MS), monoclonal paraprotein sequencing analysis, serum, results reported as baseline presence or absence of detectable clonotypic peptides
Jul-24	<b>0451U</b>	Oncology (multiple myeloma), LC-MS/MS, peptide ion quantification, serum, results compared with baseline to determine monoclonal paraprotein abundance
Jul-24	<b>0452U</b>	Oncology (bladder), methylated PENK DNA detection by linear target enrichment-quantitative methylation-specific real-time PCR (LTE-qMSP), urine, reported as likelihood of bladder cancer
Jul-24	<b>0453U</b>	Oncology (colorectal cancer), cell-free DNA (cfDNA), methylation-based quantitative PCR assay (SEPTIN9, IKZF1, BCAT1, Septin9-2, VAV3, BCAN), plasma, reported as presence or absence of circulating tumor DNA (ctDNA)
Jul-24	<b>0454U</b>	Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping
Jul-24	<b>0455U</b>	Infectious agents (sexually transmitted infection), Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis, multiplex amplified probe technique, vaginal, endocervical, gynecological specimens, oropharyngeal swabs, rectal swabs, female or male urine, each pathogen reported as detected or not detected
Jul-24	<b>0457U</b>	Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 9 PFAS compounds by LC-MS/MS, plasma or serum, quantitative
Jul-24	<b>0458U</b>	Oncology (breast cancer), S100A8 and S100A9, by enzyme-linked immunosorbent assay (ELISA), tear fluid with age, algorithm

		reported as a risk score
Jul-24	<b>0459U</b>	B-amyloid (Abeta42) and total tau (tTau), electrochemiluminescent immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology
Jul-24	<b>0460U</b>	Oncology, whole blood or buccal, DNA single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, with variant analysis and reported phenotypes
Jul-24	<b>0461U</b>	Oncology, pharmacogenomic analysis of single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, whole blood or buccal swab, with variant analysis, including impacted gene-drug interactions and reported phenotypes
Jul-24	<b>0462U</b>	Melatonin levels test, sleep study, 7 or 9 sample melatonin profile (cortisol optional), enzyme-linked immunosorbent assay (ELISA), saliva, screening/preliminary
Jul-24	<b>0463U</b>	Oncology (cervix), mRNA gene expression profiling of 14 biomarkers (E6 and E7 of the highest-risk human papillomavirus [HPV] types 16, 18, 31, 33, 45, 52, 58), by real-time nucleic acid sequence-based amplification (NASBA), exo- or endocervical epithelial cells, algorithm reported as positive or negative for increased risk of cervical dysplasia or cancer for each biomarker
Jul-24	<b>0464U</b>	Oncology (colorectal) screening, quantitative real-time target and signal amplification, methylated DNA markers, including LASS4, LRRC4 and PPP2R5C, a reference marker ZDHHC1, and a protein marker (fecal hemoglobin), utilizing stool, algorithm reported as a positive or negative result
Jul-24	<b>0465U</b>	Oncology (urothelial carcinoma), DNA, quantitative methylation-specific PCR of 2 genes (ONECUT2, VIM), algorithmic analysis reported as positive or negative
Jul-24	<b>0466U</b>	Cardiology (coronary artery disease [CAD]), DNA, genome-wide association studies (564856 single-nucleotide polymorphisms [SNPs], targeted variant genotyping), patient lifestyle and clinical data, buccal swab, algorithm reported as polygenic risk to acquired heart disease
Jul-24	<b>0467U</b>	Oncology (bladder), DNA, next-generation sequencing (NGS) of 60 genes and whole genome aneuploidy, urine, algorithms reported as minimal residual disease (MRD) status positive or negative and quantitative disease burden
Jul-24	<b>0468U</b>	Hepatology (nonalcoholic steatohepatitis [NASH]), miR-34a-5p, alpha 2-macroglobulin, YKL40, HbA1c, serum and whole blood, algorithm reported as a single score for NASH activity and fibrosis
Jul-24	<b>0469U</b>	Rare diseases (constitutional/heritable disorders), whole genome sequence analysis for chromosomal abnormalities, copy number variants, duplications/deletions, inversions, unbalanced translocations, regions of homozygosity (ROH), inheritance pattern that indicate uniparental disomy (UPD), and aneuploidy, fetal sample (amniotic fluid, chorionic villus sample, or products of conception), identification and categorization of genetic variants, diagnostic report of fetal results based on phenotype with maternal sample and paternal sample, if performed, as comparators and/or maternal cell contamination
Jul-24	<b>0470U</b>	Oncology (oropharyngeal), detection of minimal residual disease by next-generation sequencing (NGS) based quantitative evaluation of 8 DNA targets, cell-free HPV 16 and 18 DNA from plasma
Jul-24	<b>0471U</b>	Oncology (colorectal cancer), qualitative real-time PCR of 35 variants of KRAS and NRAS genes (exons 2, 3, 4), formalin-fixed paraffin-embedded (FFPE), predictive, identification of detected mutations
Jul-24	<b>0472U</b>	Carbonic anhydrase VI (CA VI), parotid specific/secretory protein (PSP) and salivary protein (SP1) IgG, IgM, and IgA antibodies, enzyme-linked immunosorbent assay (ELISA), semiquantitative, blood, reported as predictive evidence of early Sjogren syndrome
Jul-24	<b>0473U</b>	Oncology (solid tumor), next-generation sequencing (NGS) of DNA from formalin-fixed paraffin-embedded (FFPE) tissue with comparative sequence analysis from a matched normal specimen (blood or saliva), 648 genes, interrogation for sequence variants, insertion and deletion alterations, copy number variants, rearrangements, microsatellite instability, and tumor-mutation burden
Jul-24	<b>0474U</b>	Hereditary pan-cancer (eg, hereditary sarcomas, hereditary endocrine tumors, hereditary neuroendocrine tumors, hereditary cutaneous melanoma), genomic sequence analysis panel of 88 genes with 20 duplications/deletions using next-generation sequencing (NGS), Sanger sequencing, blood or saliva, reported as positive or negative for germline variants, each gene
Jul-24	<b>0475U</b>	Hereditary prostate cancer-related disorders, genomic sequence analysis panel using next-generation sequencing (NGS), Sanger sequencing, multiplex ligation-dependent probe amplification (MLPA), and array comparative genomic hybridization (CGH), evaluation of 23 genes and duplications/deletions when indicated, pathologic mutations reported with a genetic risk score for prostate cancer
Oct-24	<b>0476U</b>	Drug metabolism, psychiatry (eg, major depressive disorder, general anxiety disorder, attention deficit hyperactivity disorder [ADHD], schizophrenia), whole blood, buccal swab, and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant analysis and reported phenotypes
Oct-24	<b>0477U</b>	Drug metabolism, psychiatry (eg, major depressive disorder, general anxiety disorder, attention deficit hyperactivity disorder [ADHD], schizophrenia), whole blood, buccal swab, and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant analysis, including impacted gene-drug interactions and reported phenotypes
Oct-24	<b>0478U</b>	Oncology (non-small cell lung cancer), DNA and RNA, digital PCR analysis of 9 genes (EGFR, KRAS, BRAF, ALK, ROS1, RET, NTRK 1/2/3, ERBB2, and MET) in formalin-fixed paraffin-embedded (FFPE) tissue, interrogation for single-nucleotide variants, insertions/deletions, gene rearrangements, and reported as actionable detected variants for therapy selection
Oct-24	<b>0479U</b>	Tau, phosphorylated, pTau217
Oct-24	<b>0480U</b>	Infectious disease (bacteria, viruses, fungi, and parasites), cerebrospinal fluid (CSF), metagenomic next-generation sequencing (DNA and RNA), bioinformatic analysis, with positive pathogen identification
Oct-24	<b>0481U</b>	IDH1 (isocitrate dehydrogenase 1 [NADP+]), IDH2 (isocitrate dehydrogenase 2 [NADP+]), and TERT (telomerase reverse transcriptase) promoter (eg, central nervous system [CNS] tumors), next-generation sequencing (single-nucleotide variants [SNV], deletions, and insertions)
Oct-24	<b>0482U</b>	Obstetrics (preeclampsia), biochemical assay of soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF), serum, ratio reported for sFlt-1/PlGF, with risk of progression for preeclampsia with severe features within 2 weeks
Oct-24	<b>0483U</b>	Infectious disease (Neisseria gonorrhoeae), sensitivity, ciprofloxacin resistance (gyrA S91F point mutation), oral, rectal, or vaginal swab, algorithm reported as probability of fluoroquinolone resistance
Oct-24	<b>0484U</b>	Infectious disease (Mycoplasma genitalium), macrolide sensitivity (23S rRNA point mutation), oral, rectal, or vaginal swab, algorithm reported as probability of macrolide resistance
Oct-24	<b>0485U</b>	Oncology (solid tumor), cell-free DNA and RNA by next-generation sequencing, interpretative report for germline mutations, clonal

		hematopoiesis of indeterminate potential, and tumor-derived single-nucleotide variants, small insertions/deletions, copy number alterations, fusions, microsatellite instability, and tumor mutational burden
Oct-24	<b>0486U</b>	Oncology (pan-solid tumor), next-generation sequencing analysis of tumor methylation markers present in cell-free circulating tumor DNA, algorithm reported as quantitative measurement of methylation as a correlate of tumor fraction
Oct-24	<b>0487U</b>	Oncology (solid tumor), cell-free circulating DNA, targeted genomic sequence analysis panel of 84 genes, interrogation for sequence variants, aneuploidy-corrected gene copy number amplifications and losses, gene rearrangements, and microsatellite instability
Oct-24	<b>0488U</b>	Obstetrics (fetal antigen noninvasive prenatal test), cell-free DNA sequence analysis for detection of fetal presence or absence of 1 or more of the Rh, C, c, D, E, Duffy (Fya), or Kell (K) antigen in alloimmunized pregnancies, reported as selected antigen(s) detected or not detected
Oct-24	<b>0489U</b>	Obstetrics (single-gene noninvasive prenatal test), cell-free DNA sequence analysis of 1 or more targets (eg, CFTR, SMN1, HBB, HBA1, HBA2) to identify paternally inherited pathogenic variants, and relative mutation-dosage analysis based on molecular counts to determine fetal inheritance of maternal mutation, algorithm reported as a fetal risk score for the condition (eg, cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies [including sickle cell disease], alpha thalassemia)
Oct-24	<b>0490U</b>	Oncology (cutaneous or uveal melanoma), circulating tumor cell selection, morphological characterization and enumeration based on differential CD146, high molecular-weight melanoma-associated antigen, CD34 and CD45 protein biomarkers, peripheral blood
Oct-24	<b>0491U</b>	Oncology (solid tumor), circulating tumor cell selection, morphological characterization and enumeration based on differential epithelial cell adhesion molecule (EpCAM), cytokeratins 8, 18, and 19, CD45 protein biomarkers, and quantification of estrogen receptor (ER) protein biomarker-expressing cells, peripheral blood
Oct-24	<b>0492U</b>	Oncology (solid tumor), circulating tumor cell selection, morphological characterization and enumeration based on differential epithelial cell adhesion molecule (EpCAM), cytokeratins 8, 18, and 19, CD45 protein biomarkers, and quantification of PD-L1 protein biomarker-expressing cells, peripheral blood
Oct-24	<b>0493U</b>	Transplantation medicine, quantification of donor-derived cell-free DNA (cfDNA) using next-generation sequencing, plasma, reported as percentage of donor-derived cell-free DNA
Oct-24	<b>0494U</b>	Red blood cell antigen (fetal RhD gene analysis), next-generation sequencing of circulating cell-free DNA (cfDNA) of blood in pregnant individuals known to be RhD negative, reported as positive or negative
Oct-24	<b>0495U</b>	Oncology (prostate), analysis of circulating plasma proteins (tPSA, fPSA, KLK2, PSP94, and GDF15), germline polygenic risk score (60 variants), clinical information (age, family history of prostate cancer, prior negative prostate biopsy), algorithm reported as risk of likelihood of detecting clinically significant prostate cancer
Oct-24	<b>0496U</b>	Oncology (colorectal), cell-free DNA, 8 genes for mutations, 7 genes for methylation by real-time RT-PCR, and 4 proteins by enzyme-linked immunosorbent assay, blood, reported positive or negative for colorectal cancer or advanced adenoma risk
Oct-24	<b>0497U</b>	Oncology (prostate), mRNA gene-expression profiling by real-time RT-PCR of 6 genes (FOXM1, MCM3, MTUS1, TTC21B, ALAS1, and PPP2CA), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a risk score for prostate cancer
Oct-24	<b>0498U</b>	Oncology (colorectal), next-generation sequencing for mutation detection in 43 genes and methylation pattern in 45 genes, blood, and formalin-fixed paraffin-embedded (FFPE) tissue, report of variants and methylation pattern with interpretation
Oct-24	<b>0499U</b>	Oncology (colorectal and lung), DNA from formalin-fixed paraffin-embedded (FFPE) tissue, next-generation sequencing of 8 genes (NRAS, EGFR, CTNNB1, PIK3CA, APC, BRAF, KRAS, and TP53), mutation detection
Oct-24	<b>0500U</b>	Autoinflammatory disease (VEXAS syndrome), DNA, UBA1 gene mutations, targeted variant analysis (M41T, M41V, M41L, c.118-2A>C, c.118-1G>C, c.118-9_118-2del, S56F, S621C)
Oct-24	<b>0501U</b>	Oncology (colorectal), blood, quantitative measurement of cell-free DNA (cfDNA)
Oct-24	<b>0502U</b>	Human papillomavirus (HPV), E6/E7 markers for high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), cervical cells, branched-chain capture hybridization, reported as negative or positive for high risk for HPV
Oct-24	<b>0503U</b>	Neurology (Alzheimer disease), beta amyloid (AB40, AB42, AB42/40 ratio) and tau-protein (ptau217, np-tau217, ptau217/np-tau217 ratio), blood, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (LC-MS/MS), algorithm score reported as likelihood of positive or negative for amyloid plaques
Oct-24	<b>0504U</b>	Infectious disease (urinary tract infection), identification of 17 pathologic organisms, urine, real-time PCR, reported as positive or negative for each organism
Oct-24	<b>0505U</b>	Infectious disease (vaginal infection), identification of 32 pathogenic organisms, swab, real-time PCR, reported as positive or negative for each organism
Oct-24	<b>0506U</b>	Gastroenterology (Barrett's esophagus), esophageal cells, DNA methylation analysis by next-generation sequencing of at least 89 differentially methylated genomic regions, algorithm reported as likelihood for Barrett's esophagus
Oct-24	<b>0507U</b>	Oncology (ovarian), DNA, whole-genome sequencing with 5-hydroxymethylcytosine (5hmC) enrichment, using whole blood or plasma, algorithm reported as cancer detected or not detected
Oct-24	<b>0508U</b>	Transplantation medicine, quantification of donor-derived cell-free DNA using 40 single-nucleotide polymorphisms (SNPs), plasma, and urine, initial evaluation reported as percentage of donor-derived cell-free DNA with risk for active rejection
Oct-24	<b>0509U</b>	Transplantation medicine, quantification of donor-derived cell-free DNA using up to 12 single-nucleotide polymorphisms (SNPs) previously identified, plasma, reported as percentage of donor-derived cell-free DNA with risk for active rejection
Oct-24	<b>0510U</b>	Oncology (pancreatic cancer), augmentative algorithmic analysis of 16 genes from previously sequenced RNA whole-transcriptome data, reported as probability of predicted molecular subtype
Oct-24	<b>0511U</b>	Oncology (solid tumor), tumor cell culture in 3D microenvironment, 36 or more drug panel, reported as tumor-response prediction for each drug
Oct-24	<b>0512U</b>	Oncology (prostate), augmentative algorithmic analysis of digitized whole-slide imaging of histologic features for microsatellite instability (MSI) status, formalin-fixed paraffin-embedded (FFPE) tissue, reported as increased or decreased probability of MSI-high (MSI-H)
Oct-24	<b>0513U</b>	Oncology (prostate), augmentative algorithmic analysis of digitized whole-slide imaging of histologic features for microsatellite instability (MSI) and homologous recombination deficiency (HRD) status, formalin-fixed paraffin-embedded (FFPE) tissue, reported as increased or decreased probability of each biomarker

Oct-24	<b>0514U</b>	Gastroenterology (irritable bowel disease [IBD]), immunoassay for quantitative determination of adalimumab (ADL) levels in venous serum in patients undergoing adalimumab therapy, results reported as a numerical value as micrograms per milliliter (mcg/mL)
Oct-24	<b>0515U</b>	Gastroenterology (irritable bowel disease [IBD]), immunoassay for quantitative determination of infliximab (IFX) levels in venous serum in patients undergoing infliximab therapy, results reported as a numerical value as micrograms per milliliter (mcg/mL)
Oct-24	<b>0516U</b>	Drug metabolism, whole blood, pharmacogenomic genotyping of 40 genes and CYP2D6 copy number variant analysis, reported as metabolizer status
Oct-24	<b>0517U</b>	Therapeutic drug monitoring, 80 or more psychoactive drugs or substances, LC-MS/MS, plasma, qualitative and quantitative therapeutic minimally and maximally effective dose of prescribed and non-prescribed medications
Oct-24	<b>0518U</b>	Therapeutic drug monitoring, 90 or more pain and mental health drugs or substances, LC-MS/MS, plasma, qualitative and quantitative therapeutic minimally effective range of prescribed and non-prescribed medications
Oct-24	<b>0519U</b>	Therapeutic drug monitoring, medications specific to pain, depression, and anxiety, LC-MS/MS, plasma, 110 or more drugs or substances, qualitative and quantitative therapeutic minimally effective range of prescribed, non-prescribed, and illicit medications in circulation
Oct-24	<b>0520U</b>	Therapeutic drug monitoring, 200 or more drugs or substances, LC-MS/MS, plasma, qualitative and quantitative therapeutic minimally effective range of prescribed and non-prescribed medications
Jan-25	<b>0521U</b>	Rheumatoid factor IgA and IgM, cyclic citrullinated peptide (CCP) antibodies, and scavenger receptor A (SR-A) by immunoassay, blood
Jan-25	<b>0522U</b>	Carbonic anhydrase VI, parotid specific/secretory protein and salivary protein 1 (SP1), IgG, IgM, and IgA antibodies, chemiluminescence, semiquantitative, blood
Jan-25	<b>0523U</b>	Oncology (solid tumor), DNA, qualitative, next-generation sequencing (NGS) of single-nucleotide variants (SNV) and insertion/deletions in 22 genes utilizing formalin-fixed paraffin-embedded tissue, reported as presence or absence of mutation(s), location of mutation(s), nucleotide change, and amino acid change
Jan-25	<b>0524U</b>	Obstetrics (preeclampsia), sFlt-1/PlGF ratio, immunoassay, utilizing serum or plasma, reported as a value
Jan-25	<b>0525U</b>	Oncology, spheroid cell culture, 11-drug panel (carboplatin, docetaxel, doxorubicin, etoposide, gemcitabine, niraparib, olaparib, paclitaxel, rucaparib, topotecan, veliparib) ovarian, fallopian, or peritoneal response prediction for each drug
Jan-25	<b>0526U</b>	Nephrology (renal transplant), quantification of CXCL10 chemokines, flow cytometry, urine, reported as pg/mL creatinine baseline and monitoring over time
Jan-25	<b>0527U</b>	Herpes simplex virus (HSV) types 1 and 2 and Varicella zoster virus (VZV), amplified probe technique, each pathogen reported as detected or not detected
Jan-25	<b>0528U</b>	Lower respiratory tract infectious agent detection, 18 bacteria, 8 viruses, and 7 antimicrobial-resistance genes, amplified probe technique, including reverse transcription for RNA targets, each analyte reported as detected or not detected with semiquantitative results for 15 bacteria
Jan-25	<b>0529U</b>	Hematology (venous thromboembolism [VTE]), genome-wide single-nucleotide polymorphism variants, including F2 and F5 gene analysis, and Leiden variant, by microarray analysis, saliva, report as risk score for VTE
Jan-25	<b>0530U</b>	Oncology (pan-solid tumor), ctDNA, utilizing plasma, next-generation sequencing (NGS) of 77 genes, 8 fusions, microsatellite instability, and tumor mutation burden, interpretative report for single-nucleotide variants, copy-number alterations, with therapy association
Jul-24	<b>0867T</b>	Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance; prostate volume greater or equal to 50 mL
Jul-24	<b>0868T</b>	High-resolution gastric electrophysiology mapping with simultaneous patient-symptom profiling, with interpretation and report
Jul-24	<b>0869T</b>	Injection(s), bone-substitute material for bone and/or soft tissue hardware fixation augmentation, including intraoperative imaging guidance, when performed
Jul-24	<b>0870T</b>	Implantation of subcutaneous peritoneal ascites pump system, percutaneous, including pump-pocket creation, insertion of tunneled indwelling bladder and peritoneal catheters with pump connections, including all imaging and initial programming, when performed
Jul-24	<b>0871T</b>	Replacement of a subcutaneous peritoneal ascites pump, including reconnection between pump and indwelling bladder and peritoneal catheters, including initial programming and imaging, when performed
Jul-24	<b>0872T</b>	Replacement of indwelling bladder and peritoneal catheters, including tunneling of catheter(s) and connection with previously implanted peritoneal ascites pump, including imaging and programming, when performed
Jul-24	<b>0873T</b>	Revision of a subcutaneously implanted peritoneal ascites pump system, any component (ascites pump, associated peritoneal catheter, associated bladder catheter), including imaging and programming, when performed
Jul-24	<b>0874T</b>	Removal of a peritoneal ascites pump system, including implanted peritoneal ascites pump and indwelling bladder and peritoneal catheters
Jul-24	<b>0875T</b>	Programming of subcutaneously implanted peritoneal ascites pump system by physician or other qualified health care professional
Jul-24	<b>0876T</b>	Duplex scan of hemodialysis fistula, computer-aided, limited (volume flow, diameter, and depth, including only body of fistula)
Jul-24	<b>0877T</b>	Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained without concurrent CT examination of any structure contained in previously acquired diagnostic imaging
Jul-24	<b>0878T</b>	Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained with concurrent CT examination of the same structure
Jul-24	<b>0879T</b>	Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmission
Jul-24	<b>0880T</b>	Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and report
Jul-24	<b>0881T</b>	Cryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance to treatment, and removal of the oral device



Jul-24	<b>0882T</b>	Intraoperative therapeutic electrical stimulation of peripheral nerve to promote nerve regeneration, including lead placement and removal, upper extremity, minimum of 10 minutes; initial nerve (List separately in addition to code for primary procedure)
Jul-24	<b>0883T</b>	Intraoperative therapeutic electrical stimulation of peripheral nerve to promote nerve regeneration, including lead placement and removal, upper extremity, minimum of 10 minutes; each additional nerve (List separately in addition to code for primary procedure)
Jul-24	<b>0884T</b>	Esophagoscopy, flexible, transoral, with initial transendoscopic mechanical dilation (eg, nondrug-coated balloon) followed by therapeutic drug delivery by drug-coated balloon catheter for esophageal stricture, including fluoroscopic guidance, when performed
Jul-24	<b>0885T</b>	Colonoscopy, flexible, with initial transendoscopic mechanical dilation (eg, nondrug-coated balloon) followed by therapeutic drug delivery by drug-coated balloon catheter for colonic stricture, including fluoroscopic guidance, when performed
Jul-24	<b>0886T</b>	Sigmoidoscopy, flexible, with initial transendoscopic mechanical dilation (eg, nondrug-coated balloon) followed by therapeutic drug delivery by drug-coated balloon catheter for colonic stricture, including fluoroscopic guidance, when performed
Jul-24	<b>0887T</b>	End-tidal control of inhaled anesthetic agents and oxygen to assist anesthesia care delivery (List separately in addition to code for primary procedure)
Jul-24	<b>0888T</b>	Histotripsy (ie, non-thermal ablation via acoustic energy delivery) of malignant renal tissue, including imaging guidance
Jul-24	<b>0889T</b>	Personalized target development for accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation derived from a structural and resting-state functional MRI, including data preparation and transmission, generation of the target, motor threshold-starting location, neuronavigation files and target report, review and interpretation
Jul-24	<b>0890T</b>	Accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation, including target assessment, initial motor threshold determination, neuronavigation, delivery and management, initial treatment day
Jul-24	<b>0891T</b>	Accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation, including neuronavigation, delivery and management, subsequent treatment day
Jul-24	<b>0892T</b>	Accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation, including neuronavigation, delivery and management, subsequent motor threshold redetermination with delivery and management, per treatment day
Jul-24	<b>0893T</b>	Noninvasive assessment of blood oxygenation, gas exchange efficiency, and cardiorespiratory status, with physician or other qualified health care professional interpretation and report
Jul-24	<b>0894T</b>	Cannulation of the liver allograft in preparation for connection to the normothermic perfusion device and decannulation of the liver allograft following normothermic perfusion
Jul-24	<b>0895T</b>	Connection of liver allograft to normothermic machine perfusion device, hemostasis control; initial 4 hours of monitoring time, including hourly physiological and laboratory assessments (eg, perfusate temperature, perfusate pH, hemodynamic parameters, bile production, bile pH, bile glucose, biliary bicarbonate, lactate levels, macroscopic assessment)
Jul-24	<b>0896T</b>	Connection of liver allograft to normothermic machine perfusion device, hemostasis control; each additional hour, including physiological and laboratory assessments (eg, perfusate temperature, perfusate pH, hemodynamic parameters, bile production, bile pH, bile glucose, biliary bicarbonate, lactate levels, macroscopic assessment) (List separately in addition to code for primary procedure)
Jul-24	<b>0897T</b>	Noninvasive augmentative arrhythmia analysis derived from quantitative computational cardiac arrhythmia simulations, based on selected intervals of interest from 12-lead electrocardiogram and uploaded clinical parameters, including uploading clinical parameters with interpretation and report
Jul-24	<b>0898T</b>	Noninvasive prostate cancer estimation map, derived from augmentative analysis of image-guided fusion biopsy and pathology, including visualization of margin volume and location, with margin determination and physician interpretation and report
Jul-24	<b>0899T</b>	Noninvasive determination of absolute quantitation of myocardial blood flow (AQMBF), derived from augmentative algorithmic analysis of the dataset acquired via contrast cardiac magnetic resonance (CMR), pharmacologic stress, with interpretation and report by a physician or other qualified health care professional (List separately in addition to code for primary procedure)
Jul-24	<b>0900T</b>	Noninvasive estimate of absolute quantitation of myocardial blood flow (AQMBF), derived from assistive algorithmic analysis of the dataset acquired via contrast cardiac magnetic resonance (CMR), pharmacologic stress, with interpretation and report by a physician or other qualified health care professional (List separately in addition to code for primary procedure)
Jan-25	<b>0901T</b>	Placement of bone marrow sampling port, including imaging guidance when performed
Jan-25	<b>0902T</b>	QTc interval derived by augmentative algorithmic analysis of input from an external, patient-activated mobile ECG device
Jan-25	<b>0903T</b>	Electrocardiogram, algorithmically generated 12-lead ECG from a reduced-lead ECG; with interpretation and report
Jan-25	<b>0904T</b>	Electrocardiogram, algorithmically generated 12-lead ECG from a reduced-lead ECG; tracing only
Jan-25	<b>0905T</b>	Electrocardiogram, algorithmically generated 12-lead ECG from a reduced-lead ECG; interpretation and report only
Jan-25	<b>0906T</b>	Concurrent optical and magnetic stimulation (COMS) therapy, wound assessment and dressing care; first application, total wound(s) surface area less than or equal to 50 sq cm
Jan-25	<b>0907T</b>	Concurrent optical and magnetic stimulation (COMS) therapy, wound assessment and dressing care; each additional application, total wound(s) surface area less than or equal to 50 sq cm (List separately in addition to code for primary procedure)
Jan-25	<b>0908T</b>	Open implantation of integrated neurostimulation system, vagus nerve, including analysis and programming, when performed
Jan-25	<b>0909T</b>	Replacement of integrated neurostimulation system, vagus nerve, including analysis and programming, when performed
Jan-25	<b>0910T</b>	Removal of integrated neurostimulation system, vagus nerve
Jan-25	<b>0911T</b>	Electronic analysis of implanted integrated neurostimulation system, vagus nerve; without programming by physician or other qualified health care professional
Jan-25	<b>0912T</b>	Electronic analysis of implanted integrated neurostimulation system, vagus nerve; with simple programming by physician or other qualified health care professional
Jan-25	<b>0913T</b>	Percutaneous transcatheter therapeutic drug delivery by intracoronary drug-delivery balloon (eg, drug-coated, drug-eluting), including mechanical dilation by nondrug-delivery balloon angioplasty, endoluminal imaging using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) when performed, imaging supervision, interpretation, and report, single major coronary artery or branch
Jan-25	<b>0914T</b>	Percutaneous transcatheter therapeutic drug delivery by intracoronary drug-delivery balloon (eg, drug-coated, drug-eluting)

		performed on a separate target lesion from the target lesion treated with balloon angioplasty, coronary stent placement or coronary atherectomy, including mechanical dilation by nondrug-delivery balloon angioplasty, endoluminal imaging using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) when performed, imaging supervision, interpretation, and report, single major coronary artery or branch (List separately in addition to code for percutaneous coronary stent or atherectomy intervention)
Jan-25	<b>0915T</b>	Insertion of permanent cardiac contractility modulation-defibrillation system component(s), including fluoroscopic guidance, and evaluation and programming of sensing and therapeutic parameters; pulse generator and dual transvenous electrodes/leads (pacing and defibrillation)
Jan-25	<b>0916T</b>	Insertion of permanent cardiac contractility modulation-defibrillation system component(s), including fluoroscopic guidance, and evaluation and programming of sensing and therapeutic parameters; pulse generator only
Jan-25	<b>0917T</b>	Insertion of permanent cardiac contractility modulation-defibrillation system component(s), including fluoroscopic guidance, and evaluation and programming of sensing and therapeutic parameters; single transvenous lead (pacing or defibrillation) only
Jan-25	<b>0918T</b>	Insertion of permanent cardiac contractility modulation-defibrillation system component(s), including fluoroscopic guidance, and evaluation and programming of sensing and therapeutic parameters; dual transvenous leads (pacing and defibrillation) only
Jan-25	<b>0919T</b>	Removal of a permanent cardiac contractility modulation-defibrillation system component(s); pulse generator only
Jan-25	<b>0920T</b>	Removal of a permanent cardiac contractility modulation-defibrillation system component(s); single transvenous pacing lead only
Jan-25	<b>0921T</b>	Removal of a permanent cardiac contractility modulation-defibrillation system component(s); single transvenous defibrillation lead only
Jan-25	<b>0922T</b>	Removal of a permanent cardiac contractility modulation-defibrillation system component(s); dual (pacing and defibrillation) transvenous leads only
Jan-25	<b>0923T</b>	Removal and replacement of permanent cardiac contractility modulation-defibrillation pulse generator only
Jan-25	<b>0924T</b>	Repositioning of previously implanted cardiac contractility modulation-defibrillation transvenous electrode(s)/lead(s), including fluoroscopic guidance and programming of sensing and therapeutic parameters
Jan-25	<b>0925T</b>	Relocation of skin pocket for implanted cardiac contractility modulation-defibrillation pulse generator
Jan-25	<b>0926T</b>	Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, implantable cardiac contractility modulation-defibrillation system
Jan-25	<b>0927T</b>	Interrogation device evaluation (in person) with analysis, review, and report, including connection, recording, and disconnection, per patient encounter, implantable cardiac contractility modulation-defibrillation system
Jan-25	<b>0928T</b>	Interrogation device evaluation (remote), up to 90 days, cardiac contractility modulation-defibrillation system with interim analysis and report(s) by a physician or other qualified health care professional
Jan-25	<b>0929T</b>	Interrogation device evaluation (remote), up to 90 days, cardiac contractility modulation-defibrillation system, remote data acquisition(s), receipt of transmissions, technician review, technical support, and distribution of results
Jan-25	<b>0930T</b>	Electrophysiologic evaluation of cardiac contractility modulation-defibrillator leads, including defibrillation-threshold evaluation (induction of arrhythmia, evaluation of sensing and therapy for arrhythmia termination), at time of initial implantation or replacement with testing of cardiac contractility modulation-defibrillator pulse generator
Jan-25	<b>0931T</b>	Electrophysiologic evaluation of cardiac contractility modulation-defibrillator leads, including defibrillation-threshold evaluation (induction of arrhythmia, evaluation of sensing and therapy for arrhythmia termination), separate from initial implantation or replacement with testing of cardiac contractility modulation-defibrillator pulse generator
Jan-25	<b>0932T</b>	Noninvasive detection of heart failure derived from augmentative analysis of an echocardiogram that demonstrated preserved ejection fraction, with interpretation and report by a physician or other qualified health care professional
Jan-25	<b>0933T</b>	Transcatheter implantation of wireless left atrial pressure sensor for long-term left atrial pressure monitoring, including sensor calibration and deployment, right heart catheterization, transseptal puncture, imaging guidance, and radiological supervision and interpretation
Jan-25	<b>0934T</b>	Remote monitoring of a wireless left atrial pressure sensor for up to 30 days, including data from daily uploads of left atrial pressure recordings, interpretation(s) and trend analysis, with adjustments to the diuretics plan, treatment paradigm thresholds, medications or lifestyle modifications, when performed, and report(s) by a physician or other qualified health care professional
Jan-25	<b>0935T</b>	Cystourethroscopy with renal pelvic sympathetic denervation, radiofrequency ablation, retrograde ureteral approach, including insertion of guide wire, selective placement of ureteral sheath(s) and multiple conformable electrodes, contrast injection(s), and fluoroscopy, bilateral
Jan-25	<b>0936T</b>	Photobiomodulation therapy of retina, single session
Jan-25	<b>0937T</b>	External electrocardiographic recording for greater than 15 days up to 30 days by continuous rhythm recording and storage; including recording, scanning analysis with report, review and interpretation by a physician or other qualified health care professional
Jan-25	<b>0938T</b>	External electrocardiographic recording for greater than 15 days up to 30 days by continuous rhythm recording and storage; recording (including connection and initial recording)
Jan-25	<b>0939T</b>	External electrocardiographic recording for greater than 15 days up to 30 days by continuous rhythm recording and storage; scanning analysis with report
Jan-25	<b>0940T</b>	External electrocardiographic recording for greater than 15 days up to 30 days by continuous rhythm recording and storage; review and interpretation by a physician or other qualified health care professional
Jan-25	<b>0941T</b>	Cystourethroscopy, flexible; with insertion and expansion of prostatic urethral scaffold using integrated cystoscopic visualization
Jan-25	<b>0942T</b>	Cystourethroscopy, flexible; with removal and replacement of prostatic urethral scaffold
Jan-25	<b>0943T</b>	Cystourethroscopy, flexible; with removal of prostatic urethral scaffold
Jan-25	<b>0944T</b>	3D contour simulation of target liver lesion(s) and margin(s) for image-guided percutaneous microwave ablation
Jan-25	<b>0945T</b>	Intraoperative assessment for abnormal (tumor) tissue, in-vivo, following partial mastectomy (eg, lumpectomy) using computer-aided fluorescence imaging (List separately in addition to code for primary procedure)
Jan-25	<b>0946T</b>	Orthopedic implant movement analysis using paired computed tomography (CT) examination of the target structure, including

		data acquisition, data preparation and transmission, interpretation and report (including CT scan of the joint or extremity performed with paired views)
Jan-25	<b>0947T</b>	Magnetic resonance image guided low intensity focused ultrasound (MRgFUS), stereotactic blood-brain barrier disruption using microbubble resonators to increase the concentration of blood-based biomarkers of target, intracranial, including stereotactic navigation and frame placement, when performed
Apr-24	<b>A2026</b>	Restrata minimatrix, 5 mg
Oct-24	<b>A2027</b>	Matriderm, per square centimeter
Oct-24	<b>A2028</b>	Micromatrix flex, per mg
Oct-24	<b>A2029</b>	Mirotract wound matrix sheet, per cubic centimeter
Apr-24	<b>A4271</b>	Integrated lancing and blood sample testing cartridges for home blood glucose monitor, per month
Jan-24	<b>A4287</b>	Disposable collection and storage bag for breast milk, any size, any type, each
Apr-24	<b>A4438</b>	Adhesive clip applied to the skin to secure external electrical nerve stimulator controller, each
Jan-24	<b>A4457</b>	Enema tube, with or without adapter, any type, replacement only, each
Jan-24	<b>A4468</b>	Exsufflation belt, includes all supplies and accessories
Jan-24	<b>A4540</b>	Distal transcutaneous electrical nerve stimulator, stimulates peripheral nerves of the upper arm
Jan-24	<b>A4541</b>	Monthly supplies for use of device coded at e0733
Jan-24	<b>A4542</b>	Supplies and accessories for external upper limb tremor stimulator of the peripheral nerves of the wrist
Oct-24	<b>A4543</b>	Supplies for transcutaneous electrical nerve stimulator, for nerves in the auricular region, per month
Oct-24	<b>A4544</b>	Electrode for external lower extremity nerve stimulator for restless legs syndrome
Oct-24	<b>A4545</b>	Supplies and accessories for external tibial nerve stimulator (e.g., socks, gel pads, electrodes, etc.), needed for one month
Apr-24	<b>A4564</b>	Pessary, disposable, any type
Apr-24	<b>A4593</b>	Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, controller
Apr-24	<b>A4594</b>	Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, mouthpiece each
Jan-24	<b>A6520</b>	Gradient compression garment, glove, padded, for nighttime use, each
Jan-24	<b>A6521</b>	Gradient compression garment, glove, padded, for nighttime use, custom, each
Jan-24	<b>A6522</b>	Gradient compression garment, arm, padded, for nighttime use, each
Jan-24	<b>A6523</b>	Gradient compression garment, arm, padded, for nighttime use, custom, each
Jan-24	<b>A6524</b>	Gradient compression garment, lower leg and foot, padded, for nighttime use, each
Jan-24	<b>A6525</b>	Gradient compression garment, lower leg and foot, padded, for nighttime use, custom, each
Jan-24	<b>A6526</b>	Gradient compression garment, full leg and foot, padded, for nighttime use, each
Jan-24	<b>A6527</b>	Gradient compression garment, full leg and foot, padded, for nighttime use, custom, each
Jan-24	<b>A6528</b>	Gradient compression garment, bra, for nighttime use, each
Jan-24	<b>A6529</b>	Gradient compression garment, bra, for nighttime use, custom, each
Jan-24	<b>A6552</b>	Gradient compression stocking, below knee, 30-40 mmhg, each
Jan-24	<b>A6553</b>	Gradient compression stocking, below knee, 30-40 mmhg, custom, each
Jan-24	<b>A6554</b>	Gradient compression stocking, below knee, 40 mmhg or greater, each
Jan-24	<b>A6555</b>	Gradient compression stocking, below knee, 40 mmhg or greater, custom, each
Jan-24	<b>A6556</b>	Gradient compression stocking, thigh length, 18-30 mmhg, custom, each
Jan-24	<b>A6557</b>	Gradient compression stocking, thigh length, 30-40 mmhg, custom, each
Jan-24	<b>A6558</b>	Gradient compression stocking, thigh length, 40 mmhg or greater, custom, each
Jan-24	<b>A6559</b>	Gradient compression stocking, full length/chap style, 18-30 mmhg, custom, each
Jan-24	<b>A6560</b>	Gradient compression stocking, full length/chap style, 30-40 mmhg, custom, each
Jan-24	<b>A6561</b>	Gradient compression stocking, full length/chap style, 40 mmhg or greater, custom, each
Jan-24	<b>A6562</b>	Gradient compression stocking, waist length, 18-30 mmhg, custom, each
Jan-24	<b>A6563</b>	Gradient compression stocking, waist length, 30-40 mmhg, custom, each
Jan-24	<b>A6564</b>	Gradient compression stocking, waist length, 40 mmhg or greater, custom, each
Jan-24	<b>A6565</b>	Gradient compression gauntlet, custom, each
Jan-24	<b>A6566</b>	Gradient compression garment, neck/head, each
Jan-24	<b>A6567</b>	Gradient compression garment, neck/head, custom, each
Jan-24	<b>A6568</b>	Gradient compression garment, torso and shoulder, each
Jan-24	<b>A6569</b>	Gradient compression garment, torso/shoulder, custom, each
Jan-24	<b>A6570</b>	Gradient compression garment, genital region, each
Jan-24	<b>A6571</b>	Gradient compression garment, genital region, custom, each
Jan-24	<b>A6572</b>	Gradient compression garment, toe caps, each
Jan-24	<b>A6573</b>	Gradient compression garment, toe caps, custom, each
Jan-24	<b>A6574</b>	Gradient compression arm sleeve and glove combination, custom, each
Jan-24	<b>A6575</b>	Gradient compression arm sleeve and glove combination, each
Jan-24	<b>A6576</b>	Gradient compression arm sleeve, custom, medium weight, each
Jan-24	<b>A6577</b>	Gradient compression arm sleeve, custom, heavy weight, each
Jan-24	<b>A6578</b>	Gradient compression arm sleeve, each

Jan-24	<b>A6579</b>	Gradient compression glove, custom, medium weight, each
Jan-24	<b>A6580</b>	Gradient compression glove, custom, heavy weight, each
Jan-24	<b>A6581</b>	Gradient compression glove, each
Jan-24	<b>A6582</b>	Gradient compression gauntlet, each
Jan-24	<b>A6583</b>	Gradient compression wrap with adjustable straps, below knee, 30-50 mmhg, each
Jan-24	<b>A6584</b>	Gradient compression wrap with adjustable straps, not otherwise specified
Jan-24	<b>A6585</b>	Gradient pressure wrap with adjustable straps, above knee, each
Jan-24	<b>A6586</b>	Gradient pressure wrap with adjustable straps, full leg, each
Jan-24	<b>A6587</b>	Gradient pressure wrap with adjustable straps, foot, each
Jan-24	<b>A6588</b>	Gradient pressure wrap with adjustable straps, arm, each
Jan-24	<b>A6589</b>	Gradient pressure wrap with adjustable straps, bra, each
Jan-24	<b>A6593</b>	Accessory for gradient compression garment or wrap with adjustable straps, not-otherwise specified
Jan-24	<b>A6594</b>	Gradient compression bandaging supply, bandage liner, lower extremity, any size or length, each
Jan-24	<b>A6595</b>	Gradient compression bandaging supply, bandage liner, upper extremity, any size or length, each
Jan-24	<b>A6596</b>	Gradient compression bandaging supply, conforming gauze, per linear yard, any width, each
Jan-24	<b>A6597</b>	Gradient compression bandage roll, elastic long stretch, linear yard, any width, each
Jan-24	<b>A6598</b>	Gradient compression bandage roll, elastic medium stretch, per linear yard, any width, each
Jan-24	<b>A6599</b>	Gradient compression bandage roll, inelastic short stretch, per linear yard, any width, each
Jan-24	<b>A6600</b>	Gradient compression bandaging supply, high density foam sheet, per 250 square centimeters, each
Jan-24	<b>A6601</b>	Gradient compression bandaging supply, high density foam pad, any size or shape, each
Jan-24	<b>A6602</b>	Gradient compression bandaging supply, high density foam roll for bandage, per linear yard, any width, each
Jan-24	<b>A6603</b>	Gradient compression bandaging supply, low density channel foam sheet, per 250 square centimeters, each
Jan-24	<b>A6604</b>	Gradient compression bandaging supply, low density flat foam sheet, per 250 square centimeters, each
Jan-24	<b>A6605</b>	Gradient compression bandaging supply, padded foam, per linear yard, any width, each
Jan-24	<b>A6606</b>	Gradient compression bandaging supply, padded textile, per linear yard, any width, each
Jan-24	<b>A6607</b>	Gradient compression bandaging supply, tubular protective absorption layer, per linear yard, any width, each
Jan-24	<b>A6608</b>	Gradient compression bandaging supply, tubular protective absorption padded layer, per linear yard, any width, each
Jan-24	<b>A6609</b>	Gradient compression bandaging supply, not otherwise specified
Jan-24	<b>A6610</b>	Gradient compression stocking, below knee, 18-30 mmhg, custom, each
Oct-24	<b>A7021</b>	Supplies and accessories for lung expansion airway clearance, continuous high frequency oscillation, and nebulization device (e.g., handset, nebulizer kit, biofilter)
Jan-24	<b>A7023</b>	Mechanical allergen particle barrier/inhalation filter, cream, nasal, topical
Apr-24	<b>A9293</b>	Fertility cycle (contraception & conception) tracking software application, fda cleared, per month, includes accessories (e.g., thermometer)
Jul-24	<b>A9506</b>	Graphite crucible for preparation of technetium tc 99m-labeled carbon aerosol, one crucible
Jan-24	<b>A9608</b>	Flotufolastat f 18, diagnostic, 1 millicurie
Jan-24	<b>A9609</b>	Fludeoxyglucose f18 up to 15 millicuries
Oct-24	<b>A9610</b>	Xenon xe-129 hyperpolarized gas, diagnostic, per study dose
Jan-25	<b>A9615</b>	Injection, pegulicianine, 1 mg
Jan-24	<b>C1600</b>	Catheter, transluminal intravascular lesion preparation device, bladed, sheathed (insertable)
Jan-24	<b>C1601</b>	Endoscope, single-use (i.e. disposable), pulmonary, imaging/illumination device (insertable)
Jan-24	<b>C1602</b>	Orthopedic/device/drug matrix/absorbable bone void filler, antimicrobial-eluting (implantable)
Jan-24	<b>C1603</b>	Retrieval device, insertable, laser (used to retrieve intravascular inferior vena cava filter)
Jan-24	<b>C1604</b>	Graft, transmural transvenous arterial bypass (implantable), with all delivery system components
Jul-24	<b>C1605</b>	Pacemaker, leadless, dual chamber (right atrial and right ventricular implantable components), rate-responsive, including all necessary components for implantation
Jul-24	<b>C1606</b>	Adapter, single-use (i.e. disposable), for attaching ultrasound system to upper gastrointestinal endoscope
Jan-25	<b>C1735</b>	Catheter(s), intravascular for renal denervation, radiofrequency, including all single use system components
Jan-25	<b>C1736</b>	Catheter(s), intravascular for renal denervation, ultrasound, including all single use system components
Jan-25	<b>C1737</b>	Joint fusion and fixation device(s), sacroiliac and pelvis, including all system components (implantable)
Jan-25	<b>C1738</b>	Powered, single-use (i.e. disposable) endoscopic ultrasound-guided biopsy device
Jan-25	<b>C1739</b>	Tissue marker, imaging and non-imaging device (implantable)
Jan-24	<b>C7556</b>	Bronchoscopy, rigid or flexible, with bronchial alveolar lavage and transendoscopic endobronchial ultrasound (ebus) during bronchoscopic diagnostic or therapeutic intervention(s) for peripheral lesion(s), including fluoroscopic guidance, when performed
Jan-24	<b>C7557</b>	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed and intraprocedural coronary fractional flow reserve (ffr) with 3d functional mapping of color-coded ffr values for the coronary tree, derived from coronary angiogram data, for real-time review and interpretation of possible atherosclerotic stenosis(es) intervention
Jan-24	<b>C7558</b>	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation with right and left heart catheterization including intraprocedural injection(s)



		for left ventriculography, when performed, catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) with bypass graft angiography with pharmacologic agent administration (eg, inhaled nitric oxide, intravenous infusion of nitroprusside, dobutamine, milrinone, or other agent) including assessing hemodynamic measurements before, during, after and repeat pharmacologic agent administration, when performed
Jan-24	<b>C7560</b>	Endoscopic retrograde cholangiopancreatography (ercp) with removal of foreign body(s) or stent(s) from biliary/pancreatic duct(s) and endoscopic cannulation of papilla with direct visualization of pancreatic/common bile duct(s)
Jan-25	<b>C7562</b>	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed with intraprocedural coronary fractional flow reserve (ffr) with 3d functional mapping of color-coded ffr values for the coronary tree, derived from coronary angiogram data, for real-time review and interpretation of possible atherosclerotic stenosis(es) intervention
Jan-25	<b>C7563</b>	Transluminal balloon angioplasty (except lower extremity artery(ies) for occlusive disease, intracranial, coronary, pulmonary, or dialysis circuit), open or percutaneous, including all imaging and radiological supervision and interpretation necessary to perform the angioplasty within the same artery, initial artery and all additional arteries
Jan-25	<b>C7564</b>	Percutaneous transluminal mechanical thrombectomy, vein(s), including intraprocedural pharmacological thrombolytic injections and fluoroscopic guidance with intravascular ultrasound (noncoronary vessel(s)) during diagnostic evaluation and/or therapeutic intervention, including radiological supervision and interpretation
Jan-25	<b>C7565</b>	Repair of anterior abdominal hernia(s) (ie, epigastric, incisional, ventral, umbilical, spigelian), any approach (i.e., open, laparoscopic, robotic), recurrent, including implantation of mesh or other prosthesis when performed, total length of defect(s) less than 3 cm, reducible with removal of total or near total non-infected mesh or other prosthesis at the time of initial or recurrent anterior abdominal hernia repair or parastomal hernia repair
Jan-24	<b>C7903</b>	Group psychotherapy service for diagnosis, evaluation, or treatment of a mental health or substance use disorder provided remotely by hospital staff who are licensed to provide mental health services under applicable state law(s), when the patient is in their home, and there is no associated professional service
Oct-24	<b>C8000</b>	Support device, extravascular, for arteriovenous fistula (implantable)
Jan-25	<b>C8001</b>	3d anatomical segmentation imaging for preoperative planning, data preparation and transmission, obtained from previous diagnostic computed tomographic or magnetic resonance examination of the same anatomy
Jan-25	<b>C8002</b>	Preparation of skin cell suspension autograft, automated, including all enzymatic processing and device components (do not report with manual suspension preparation)
Jan-25	<b>C8003</b>	Implantation of medial knee extraarticular implantable shock absorber spanning the knee joint from distal femur to proximal tibia, open, includes measurements, positioning and adjustments, with imaging guidance (e.g., fluoroscopy)
Jan-24	<b>C9159</b>	Injection, prothrombin complex concentrate (human), balfaxar, per i.u. of factor ix activity
Jan-24	<b>C9160</b>	Injection, daxibotulinumtoxina-lanm, 1 unit
Jan-24	<b>C9161</b>	Injection, aflibercept hd, 1 mg
Jan-24	<b>C9162</b>	Injection, avacincaptad pegol, 0.1 mg
Jan-24	<b>C9163</b>	Injection, talquetamab-tgvs, 0.25 mg
Jan-24	<b>C9164</b>	Cantharidin for topical administration, 0.7%, single unit dose applicator (3.2 mg)
Jan-24	<b>C9165</b>	Injection, elranatamab-bcmm, 1 mg
Apr-24	<b>C9166</b>	Injection, secukinumab, intravenous, 1 mg
Apr-24	<b>C9167</b>	Injection, adamts13, recombinant-krhn, 10 iu
Apr-24	<b>C9168</b>	Injection, mirikizumab-mrkz, 1 mg
Oct-24	<b>C9169</b>	Injection, nogapendekin alfa inbakicept-prln, for intravesical use, 1 microgram
Oct-24	<b>C9170</b>	Injection, tarlatamab-dlle, 1 mg
Oct-24	<b>C9171</b>	Injection, pegulicianine, 1 mg
Oct-24	<b>C9172</b>	Injection, fidanacogene elaparovvec-dzkt, per therapeutic dose
Jan-25	<b>C9173</b>	Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram
Jan-25	<b>C9610</b>	Catheter, transluminal drug delivery with or without angioplasty, coronary, non-laser (insertable)
Jan-24	<b>C9793</b>	3d predictive model generation for pre-planning of a cardiac procedure, using data from cardiac computed tomographic angiography with report
Jan-24	<b>C9794</b>	Therapeutic radiology simulation-aided field setting; complex, including acquisition of pet and ct imaging data required for radiopharmaceutical-directed radiation therapy treatment planning (i.e., modeling)
Jan-24	<b>C9795</b>	Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance and real-time positron emissions-based delivery adjustments to 1 or more lesions, entire course not to exceed 5 fractions
Apr-24	<b>C9796</b>	Repair of enterocutaneous fistula small intestine or colon (excluding anorectal fistula) with plug (e.g., porcine small intestine submucosa [sis])
Apr-24	<b>C9797</b>	Vascular embolization or occlusion procedure with use of a pressure-generating catheter (e.g., one-way valve, intermittently occluding), inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; for tumors, organ ischemia, or infarction
Jan-25	<b>C9804</b>	Elastomeric infusion pump (e.g., on-a* pump with bolus), including catheter and all disposable system components, non-opioid medical device (must be a qualifying medicare non-opioid medical device for post-surgical pain relief in accordance with section 4135 of the caa, 2023)
Jan-25	<b>C9806</b>	Rotary peristaltic infusion pump (e.g., ambit pump), including catheter and all disposable system components, non-opioid medical device (must be a qualifying medicare non-opioid medical device for post-surgical pain relief in accordance with section 4135 of the caa, 2023)
Jan-25	<b>C9807</b>	Nerve stimulator, percutaneous, peripheral (e.g., sprint peripheral nerve stimulation system), including electrode and all disposable system components, non-opioid medical device (must be a qualifying medicare non-opioid medical device for post-

		surgical pain relief in accordance with section 4135 of the caa, 2023)
Jan-25	<b>C9808</b>	Nerve cryoablation probe (e.g., cryoice, cryosphere, cryosphere max, cryoice cryosphere, cryoice cryo2), including probe and all disposable system components, non-opioid medical device (must be a qualifying medicare non-opioid medical device for post-surgical pain relief in accordance with section 4135 of the caa, 2023)
Jan-25	<b>C9809</b>	Cryoablation needle (e.g., iovera system), including needle/tip and all disposable system components, non-opioid medical device (must be a qualifying medicare non-opioid medical device for post-surgical pain relief in accordance with section 4135 of the caa, 2023)
Jul-24	<b>C9901</b>	Endoscopic defect closure within the entire gastrointestinal tract, including upper endoscopy (including diagnostic, if performed) or colonoscopy (including diagnostic, if performed), with all system and tissue anchoring components
Apr-24	<b>E0152</b>	Walker, battery powered, wheeled, folding, adjustable or fixed height
Apr-24	<b>E0468</b>	Home ventilator, dual-function respiratory device, also performs additional function of cough stimulation, includes all accessories, components and supplies for all functions
Oct-24	<b>E0469</b>	Lung expansion airway clearance, continuous high frequency oscillation, and nebulization device
Jan-24	<b>E0492</b>	Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, controlled by phone application
Jan-24	<b>E0493</b>	Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by phone application, 90-day supply
Jan-24	<b>E0530</b>	Electronic positional obstructive sleep apnea treatment, with sensor, includes all components and accessories, any type
Jan-24	<b>E0678</b>	Non-pneumatic sequential compression garment, full leg
Jan-24	<b>E0679</b>	Non-pneumatic sequential compression garment, half leg
Jan-24	<b>E0680</b>	Non-pneumatic compression controller with sequential calibrated gradient pressure
Jan-24	<b>E0681</b>	Non-pneumatic compression controller without calibrated gradient pressure
Jan-24	<b>E0682</b>	Non-pneumatic sequential compression garment, full arm
Oct-24	<b>E0683</b>	Non-pneumatic, non-sequential, peristaltic wave compression pump
Oct-24	<b>E0715</b>	Intravaginal device intended to strengthen pelvic floor muscles during kegel exercises
Oct-24	<b>E0716</b>	Supplies and accessories for intravaginal device intended to strengthen pelvic floor muscles during kegel exercises
Oct-24	<b>E0721</b>	Transcutaneous electrical nerve stimulator for nerves in the auricular region
Jan-24	<b>E0732</b>	Cranial electrotherapy stimulation (ces) system, any type
Jan-24	<b>E0733</b>	Transcutaneous electrical nerve stimulator for electrical stimulation of the trigeminal nerve
Jan-24	<b>E0734</b>	External upper limb tremor stimulator of the peripheral nerves of the wrist
Jan-24	<b>E0735</b>	Non-invasive vagus nerve stimulator
Apr-24	<b>E0736</b>	Transcutaneous tibial nerve stimulator
Oct-24	<b>E0737</b>	Transcutaneous tibial nerve stimulator, controlled by phone application
Apr-24	<b>E0738</b>	Upper extremity rehabilitation system providing active assistance to facilitate muscle re-education, include microprocessor, all components and accessories
Apr-24	<b>E0739</b>	Rehab system with interactive interface providing active assistance in rehabilitation therapy, includes all components and accessories, motors, microprocessors, sensors
Oct-24	<b>E0743</b>	External lower extremity nerve stimulator for restless legs syndrome, each
Oct-24	<b>E0767</b>	Intrabuccal, systemic delivery of amplitude-modulated, radiofrequency electromagnetic field device, for cancer treatment, includes all accessories
Jan-24	<b>E1301</b>	Whirlpool tub, walk-in, portable
Jan-25	<b>E1803</b>	Dynamic adjustable elbow extension only device, includes soft interface material
Jan-25	<b>E1804</b>	Dynamic adjustable elbow flexion only device, includes soft interface material
Jan-25	<b>E1807</b>	Dynamic adjustable wrist extension only device, includes soft interface material
Jan-25	<b>E1808</b>	Dynamic adjustable wrist flexion only device, includes soft interface material
Jan-25	<b>E1813</b>	Dynamic adjustable knee extension only device, includes soft interface material
Jan-25	<b>E1814</b>	Dynamic adjustable knee flexion only device, includes soft interface material
Jan-25	<b>E1822</b>	Dynamic adjustable ankle extension only device, includes soft interface material
Jan-25	<b>E1823</b>	Dynamic adjustable ankle flexion only device, includes soft interface material
Jan-25	<b>E1826</b>	Dynamic adjustable finger extension only device, includes soft interface material
Jan-25	<b>E1827</b>	Dynamic adjustable finger flexion only device, includes soft interface material
Jan-25	<b>E1828</b>	Dynamic adjustable toe extension only device, includes soft interface material
Jan-25	<b>E1829</b>	Dynamic adjustable toe flexion only device, includes soft interface material
Jan-24	<b>E2001</b>	Suction pump, home model, portable or stationary, electric, any type, for use with external urine management system
Apr-24	<b>E2104</b>	Home blood glucose monitor for use with integrated lancing/blood sample testing cartridge
Apr-24	<b>E2298</b>	Complex rehabilitative power wheelchair accessory, power seat elevation system, any type
Oct-24	<b>E2513</b>	Accessory for speech generating device, electromyographic sensor
Jan-24	<b>E3000</b>	Speech volume modulation system, any type, including all components and accessories
Oct-24	<b>E3200</b>	Gait modulation system, rhythmic auditory stimulation, including restricted therapy software, all components and accessories, prescription only
Jan-24	<b>G0011</b>	Individual counseling for pre-exposure prophylaxis (prep) by physician or qualified health care professional (qhp) to prevent human immunodeficiency virus (hiv), includes hiv risk assessment (initial or continued assessment of risk), hiv risk reduction and medication adherence, 15-30 minutes

Jan-24	<b>G0012</b>	Injection of pre-exposure prophylaxis (prep) drug for hiv prevention, under skin or into muscle
Jan-24	<b>G0013</b>	Individual counseling for pre-exposure prophylaxis (prep) by clinical staff to prevent human immunodeficiency virus (hiv), includes: hiv risk assessment (initial or continued assessment of risk), hiv risk reduction and medication adherence
Jan-24	<b>G0017</b>	Psychotherapy for crisis furnished in an applicable site of service (any place of service at which the non-facility rate for psychotherapy for crisis services applies, other than the office setting); first 60 minutes
Jan-24	<b>G0018</b>	Psychotherapy for crisis furnished in an applicable site of service (any place of service at which the non-facility rate for psychotherapy for crisis services applies, other than the office setting); each additional 30 minutes (list separately in addition to code for primary service)
Jan-24	<b>G0019</b>	Community health integration services performed by certified or trained auxiliary personnel, including a community health worker, under the direction of a physician or other practitioner; 60 minutes per calendar month
Jan-24	<b>G0022</b>	Community health integration services, each additional 30 minutes per calendar month (list separately in addition to g0019)
Jan-24	<b>G0023</b>	Principal illness navigation services by certified or trained auxiliary personnel under the direction of a physician or other practitioner, including a patient navigator; 60 minutes per calendar month
Jan-24	<b>G0024</b>	Principal illness navigation services, additional 30 minutes per calendar month (list separately in addition to g0023)
Jan-24	<b>G0136</b>	Administration of a standardized, evidence-based social determinants of health risk assessment tool, 5-15 minutes
Jan-24	<b>G0137</b>	Intensive outpatient services; weekly bundle, minimum of 9 services over a 7 contiguous day period, which can include individual and group therapy with physicians or psychologists (or other mental health professionals to the extent authorized under state law); occupational therapy requiring the skills of a qualified occupational therapist; services of social workers, trained psychiatric nurses, and other staff trained to work with psychiatric patients; individualized activity therapies that are not primarily recreational or diversionary; family counseling (the primary purpose of which is treatment of the individual's condition); patient training and education (to the extent that training and educational activities are closely and clearly related to individual's care and treatment); diagnostic services; and such other items and services (excluding meals and transportation) that are reasonable and necessary for the diagnosis or active treatment of the individual's condition, reasonably expected to improve or maintain the individual's condition and functional level and to prevent relapse or hospitalization, and furnished pursuant to such guidelines relating to frequency and duration of services in accordance with a physician certification and plan of treatment (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure
Apr-24	<b>G0138</b>	Intravenous infusion of ciplagliflozin alfa-atga, including provider/supplier acquisition and clinical supervision of oral administration of miglustat in preparation of receipt of ciplagliflozin alfa-atga
Jan-24	<b>G0140</b>	Principal illness navigation - peer support by certified or trained auxiliary personnel under the direction of a physician or other practitioner, including a certified peer specialist; 60 minutes per calendar month
Jan-24	<b>G0146</b>	Principal illness navigation - peer support, additional 30 minutes per calendar month (list separately in addition to g0140)
Jul-24	<b>G0519</b>	Management of new patient-caregiver dyad with dementia, low complexity, for use in cmmi model
Jul-24	<b>G0520</b>	Management of new patient-caregiver dyad with dementia, moderate complexity, for use in cmmi model
Jul-24	<b>G0521</b>	Management of new patient-caregiver dyad with dementia, high complexity, for use in cmmi model
Jul-24	<b>G0522</b>	Management of a new patient with dementia, low complexity, for use in cmmi model
Jul-24	<b>G0523</b>	Management of a new patient with dementia, moderate to high complexity, for use in cmmi model
Jul-24	<b>G0524</b>	Management of established patient-caregiver dyad with dementia, low complexity, for use in cmmi model
Jul-24	<b>G0525</b>	Management of established patient-caregiver dyad with dementia, moderate complexity, for use in cmmi model
Jul-24	<b>G0526</b>	Management of established patient-caregiver dyad with dementia, high complexity, for use in cmmi model
Jul-24	<b>G0527</b>	Management of established patient with dementia, low complexity, for use in cmmi model
Jul-24	<b>G0528</b>	Management of established patient with dementia, moderate to high complexity, for use in cmmi model
Jul-24	<b>G0529</b>	In-home respite care, 4-hour unit, for use in cmmi model
Jul-24	<b>G0530</b>	Adult day center, 8-hour unit, for use in cmmi model
Jul-24	<b>G0531</b>	Facility-based respite, 24-hour unit, for use in cmmi model
Jan-25	<b>G0532</b>	Take-home supply of nasal nalmeferene hydrochloride; one carton of two, 2.7 mg per 0.1 ml nasal sprays (provision of the services by a medicare-enrolled opioid treatment program); (list separately in addition to each primary code)
Jan-25	<b>G0533</b>	Medication assisted treatment, buprenorphine (injectable) administered on a weekly basis; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program)
Jan-25	<b>G0534</b>	Coordinated care and/or referral services, such as to adequate and accessible community resources to address unmet health-related social needs, including harm reduction interventions and recovery support services a patient needs and wishes to pursue, which significantly limit the ability to diagnose or treat an opioid use disorder; each additional 30 minutes of services (provision of the services by a medicare-enrolled opioid treatment program); (list separately in addition to each primary code)
Jan-25	<b>G0535</b>	Patient navigational services, provided directly or by referral; including helping the patient to navigate health systems and identify care providers and supportive services, to build patient self-advocacy and communication skills with care providers, and to promote patient-driven action plans and goals; each additional 30 minutes of services (provision of the services by a medicare-enrolled opioid treatment program); (list separately in addition to each primary code)
Jan-25	<b>G0536</b>	Peer recovery support services, provided directly or by referral; including leveraging knowledge of the condition or lived experience to provide support, mentorship, or inspiration to meet old treatment and recovery goals; conducting a person-centered interview to understand the patient's life story, strengths, needs, goals, preferences, and desired outcomes; developing and proposing strategies to help meet person-centered treatment goals; assisting the patient in locating or navigating recovery support services; each additional 30 minutes of services (provision of the services by a medicare-enrolled opioid treatment program); (list separately in addition to each primary code)
Jan-25	<b>G0537</b>	Administration of a standardized, evidence-based atherosclerotic cardiovascular disease (ascvd) risk assessment, 5-15 minutes, not more often than every 12 months
Jan-25	<b>G0538</b>	Atherosclerotic cardiovascular disease (ascvd) risk management services; clinical staff time; per calendar month

Jan-25	<b>G0539</b>	Caregiver training in behavior management/modification for caregiver(s) of patients with a mental or physical health diagnosis, administered by physician or other qualified health care professional (without the patient present), face-to-face; initial 30 minutes
Jan-25	<b>G0540</b>	Caregiver training in behavior management/modification for parent(s)/guardian(s)/caregiver(s) of patients with a mental or physical health diagnosis, administered by physician or other qualified health care professional (without the patient present), face-to-face; each additional 15 minutes
Jan-25	<b>G0541</b>	Caregiver training in direct care strategies and techniques to support care for patients with an ongoing condition or illness and to reduce complications (including, but not limited to, techniques to prevent decubitus ulcer formation, wound care, and infection control) (without the patient present), face-to-face; initial 30 minutes
Jan-25	<b>G0542</b>	Caregiver training in direct care strategies and techniques to support care for patients with an ongoing condition or illness and to reduce complications (including, but not limited to, techniques to prevent decubitus ulcer formation, wound care, and infection control) (without the patient present), face-to-face; each additional 15 minutes (list separately in addition to code for primary service) (use g0542 in conjunction with g0541)
Jan-25	<b>G0543</b>	Group caregiver training in direct care strategies and techniques to support care for patients with an ongoing condition or illness and to reduce complications (including, but not limited to, techniques to prevent decubitus ulcer formation, wound care, and infection control) (without the patient present), face-to-face with multiple sets of caregivers
Jan-25	<b>G0544</b>	Post discharge telephonic follow-up contacts performed in conjunction with a discharge from the emergency department for behavioral health or other crisis encounter, 4 calls per calendar month
Jan-25	<b>G0545</b>	Visit complexity inherent to hospital inpatient or observation care associated with a confirmed or suspected infectious disease by an infectious diseases specialist, including disease transmission risk assessment and mitigation, public health investigation, analysis, and testing, and complex antimicrobial therapy counseling and treatment (add-on code, list separately in addition to hospital inpatient or observation evaluation and management visit, initial, same day discharge, subsequent or discharge)
Jan-25	<b>G0546</b>	Interprofessional telephone/internet/electronic health record assessment and management service provided by a practitioner in a specialty whose covered services are limited by statute to services for the diagnosis and treatment of mental illness, including a verbal and written report to the patient's treating/requesting practitioner; 5-10 minutes of medical consultative discussion and review
Jan-25	<b>G0547</b>	Interprofessional telephone/internet/electronic health record assessment and management service provided by a practitioner in a specialty whose covered services are limited by statute to services for the diagnosis and treatment of mental illness, including a verbal and written report to the patient's treating/requesting practitioner; 11-20 minutes of medical consultative discussion and review
Jan-25	<b>G0548</b>	Interprofessional telephone/internet/electronic health record assessment and management service provided by a practitioner in a specialty whose covered services are limited by statute to services for the diagnosis and treatment of mental illness, including a verbal and written report to the patient's treating/requesting practitioner; 21-30 minutes of medical consultative discussion and review
Jan-25	<b>G0549</b>	Interprofessional telephone/internet/electronic health record assessment and management service provided by a practitioner in a specialty whose covered services are limited by statute to services for the diagnosis and treatment of mental illness, including a verbal and written report to the patient's treating/requesting practitioner; 31 or more minutes of medical consultative discussion and review
Jan-25	<b>G0550</b>	Interprofessional telephone/internet/electronic health record assessment and management service provided by a practitioner in a specialty whose covered services are limited by statute to services for the diagnosis and treatment of mental illness, including a written report to the patient's treating/requesting practitioner, 5 minutes or more of medical consultative time
Jan-25	<b>G0551</b>	Interprofessional telephone/internet/electronic health record referral service(s) provided by a treating/requesting practitioner in a specialty whose covered services are limited by statute to services for the diagnosis and treatment of mental illness, 30 minutes
Jan-25	<b>G0552</b>	Supply of digital mental health treatment device and initial education and onboarding, per course of treatment that augments a behavioral therapy plan
Jan-25	<b>G0553</b>	First 20 minutes of monthly treatment management services directly related to the patient's therapeutic use of the digital mental health treatment (dmht) device that augments a behavioral therapy plan, physician/other qualified health care professional time reviewing information related to the use of the dmht device, including patient observations and patient specific inputs in a calendar month and requiring at least one interactive communication with the patient/caregiver during the calendar month
Jan-25	<b>G0554</b>	Each additional 20 minutes of monthly treatment management services directly related to the patient's therapeutic use of the digital mental health treatment (dmht) device that augments a behavioral therapy plan, physician/other qualified health care professional time reviewing data generated from the dmht device from patient observations and patient specific inputs in a calendar month and requiring at least one interactive communication with the patient/caregiver during the calendar month
Jan-25	<b>G0555</b>	Provision of replacement patient electronics system (e.g., system pillow, handheld reader) for home pulmonary artery pressure monitoring
Jan-25	<b>G0556</b>	Advanced primary care management services for a patient with one chronic condition [expected to last at least 12 months, or until the death of the patient, which place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline], or fewer, provided by clinical staff and directed by a physician or other qualified health care professional who is responsible for all primary care and serves as the continuing focal point for all needed health care services, per calendar month
Jan-25	<b>G0557</b>	Advanced primary care management services for a patient with multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient, which place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline, provided by clinical staff and directed by a physician or other qualified health care professional who is responsible for all primary care and serves as the continuing focal point for all needed health care services, per calendar month
Jan-25	<b>G0558</b>	Advanced primary care management services for a patient that is a qualified medicare beneficiary with multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient, which place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline, provided by clinical staff and directed by a physician or other qualified health care professional who is responsible for all primary care and serves as the continuing focal point for all needed health care services, per calendar month
Jan-25	<b>G0559</b>	Post-operative follow-up visit complexity inherent to evaluation and management services addressing surgical procedure(s),



		provided by a physician or qualified health care professional who is not the practitioner who performed the procedure (or in the same group practice) and is of the same or of a different specialty than the practitioner who performed the procedure, within the 90-day global period of the procedure(s), once per 90-day global period, when there has not been a formal transfer of care
Jan-25	<b>G0560</b>	Safety planning interventions, each 20 minutes personally performed by the billing practitioner, including assisting the patient in the identification of the following personalized elements of a safety plan: recognizing warning signs of an impending suicidal or substance use-related crisis; employing internal coping strategies; utilizing social contacts and social settings as a means of distraction from suicidal thoughts or risky substance use; utilizing family members, significant others, caregivers, and/or friends to help resolve the crisis; contacting mental health or substance use disorder professionals or agencies; and making the environment safe
Jan-25	<b>G0561</b>	Tympanostomy with local or topical anesthesia and insertion of a ventilating tube when performed with tympanostomy tube delivery device, unilateral (list separately in addition to 69433) (do not use in conjunction with 0583t)
Jan-25	<b>G0562</b>	Therapeutic radiology simulation-aided field setting; complex, including acquisition of pet and ct imaging data required for radiopharmaceutical-directed radiation therapy treatment planning (i.e., modeling)
Jan-25	<b>G0563</b>	Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance and real-time positron emissions-based delivery adjustments to 1 or more lesions, entire course not to exceed 5 fractions
Jan-25	<b>G0564</b>	Creation of subcutaneous pocket with insertion of 365 day implantable interstitial glucose sensor, including system activation and patient training
Jan-25	<b>G0565</b>	Removal of implantable interstitial glucose sensor with creation of subcutaneous pocket at different anatomic site and insertion of new 365 day implantable sensor, including system activation
Jul-24	<b>G9037</b>	Interprofessional telephone/internet/electronic health record clinical question/request for specialty recommendations by a treating/requesting physician or other qualified health care professional for the care of the patient (i.e. not for professional education or scheduling) and may include subsequent follow up on the specialist's recommendations; 30 minutes
Jul-24	<b>G9038</b>	Co-management services with the following elements: new diagnosis or acute exacerbation and stabilization of existing condition; condition which may benefit from joint care planning; condition for which specialist is taking a co-management role; condition expected to last at least 3 months; comprehensive care plan established, implemented, revised or monitored in partnership with co-managing clinicians; ongoing communication and care coordination between co-managing clinicians furnishing care
Jan-24	<b>G9886</b>	Behavioral counseling for diabetes prevention, in-person, group, 60 minutes
Jan-24	<b>G9887</b>	Behavioral counseling for diabetes prevention, distance learning, 60 minutes
Jan-24	<b>G9888</b>	Maintenance 5% wl from baseline weight in months 7-12
Apr-24	<b>H0051</b>	Traditional healing service
Jan-25	<b>H0052</b>	Missing and murdered indigenous persons (mmip) mental health and clinical care
Jan-25	<b>H0053</b>	Historical trauma (ht) mental health and clinical care for indigenous persons
Oct-24	<b>J0138</b>	Injection, acetaminophen 10 mg and ibuprofen 3 mg
Jan-25	<b>J0139</b>	Injection, adalimumab, 1 mg
Oct-24	<b>J0175</b>	Injection, donanemab-azbt, 2 mg
Apr-24	<b>J0177</b>	Injection, aflibercept hd, 1 mg
Jan-24	<b>J0184</b>	Injection, amisulpride, 1 mg
Apr-24	<b>J0209</b>	Injection, sodium thiosulfate (hope), 100 mg
Jul-24	<b>J0211</b>	Injection, sodium nitrite 3 mg and sodium thiosulfate 125 mg (nithiodote)
Jan-24	<b>J0217</b>	Injection, velmanase alfa-tycv, 1 mg
Jan-24	<b>J0391</b>	Injection, artesunate, 1 mg
Jan-24	<b>J0402</b>	Injection, aripiprazole (abilify asimtufii), 1 mg
Jan-24	<b>J0576</b>	Injection, buprenorphine extended-release (brixadi), 1 mg
Apr-24	<b>J0577</b>	Injection, buprenorphine extended-release (brixadi), less than or equal to 7 days of therapy
Apr-24	<b>J0578</b>	Injection, buprenorphine extended-release (brixadi), greater than 7 days and up to 28 days of therapy
Apr-24	<b>J0589</b>	Injection, daxibotulinumtoxin-a-tanm, 1 unit
Jan-25	<b>J0601</b>	Sevelamer carbonate (renvela or therapeutically equivalent), oral, 20 mg (for esrd on dialysis)
Jan-25	<b>J0602</b>	Sevelamer carbonate (renvela or therapeutically equivalent), oral, powder, 20 mg (for esrd on dialysis)
Jan-25	<b>J0603</b>	Sevelamer hydrochloride (renagel or therapeutically equivalent), oral, 20 mg (for esrd on dialysis)
Jan-25	<b>J0605</b>	Sucroferric oxyhydroxide, oral, 5 mg (for esrd on dialysis)
Jan-25	<b>J0607</b>	Lanthanum carbonate, oral, 5 mg (for esrd on dialysis)
Jan-25	<b>J0608</b>	Lanthanum carbonate, oral, powder, 5 mg, not therapeutically equivalent to j0607 (for esrd on dialysis)
Jan-25	<b>J0609</b>	Ferric citrate, oral, 3 mg ferric iron, (for esrd on dialysis)
Jan-25	<b>J0615</b>	Calcium acetate, oral, 23 mg (for esrd on dialysis)
Apr-24	<b>J0650</b>	Injection, levothyroxine sodium, not otherwise specified, 10 mcg
Apr-24	<b>J0651</b>	Injection, levothyroxine sodium (fresenius kabi) not therapeutically equivalent to j0650, 10 mcg
Apr-24	<b>J0652</b>	Injection, levothyroxine sodium (hikma) not therapeutically equivalent to j0650, 10 mcg
Jan-25	<b>J0666</b>	Injection, bupivacaine liposome, 1 mg
Jul-24	<b>J0687</b>	Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg
Jan-24	<b>J0688</b>	Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg
Jan-24	<b>J0750</b>	Emtricitabine 200mg and tenofovir disoproxil fumarate 300mg, oral, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv)

Jan-24	<b>J0751</b>	Emtricitabine 200mg and tenofovir alafenamide 25mg, oral, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv)
Jan-24	<b>J0799</b>	Fda approved prescription drug, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv), not otherwise classified
Jan-25	<b>J0870</b>	Injection, imetelstat, 1 mg
Jul-24	<b>J0872</b>	Injection, daptomycin (xellia), unrefrigerated, not therapeutically equivalent to j0878 or j0873, 1 mg
Jan-24	<b>J0873</b>	Injection, daptomycin (xellia) not therapeutically equivalent to j0878, 1 mg
Jan-25	<b>J0901</b>	Vadadustat, oral, 1 mg (for esrd on dialysis)
Jul-24	<b>J0911</b>	Instillation, taurolidine 1.35 mg and heparin sodium 100 units (central venous catheter lock for adult patients receiving chronic hemodialysis)
Apr-24	<b>J1010</b>	Injection, methylprednisolone acetate, 1 mg
Jan-24	<b>J1105</b>	Dexmedetomidine, oral, 1 mcg
Oct-24	<b>J1171</b>	Injection, hydromorphone, 0.1 mg
Apr-24	<b>J1202</b>	Miglustat, oral, 65 mg
Apr-24	<b>J1203</b>	Injection, cipaglucosidase alfa-atga, 5 mg
Jan-24	<b>J1304</b>	Injection, tofersen, 1 mg
Jan-25	<b>J1307</b>	Injection, crovalimab-akkz, 10 mg
Apr-24	<b>J1323</b>	Injection, elranatamab-bcmm, 1 mg
Jan-24	<b>J1412</b>	Injection, valoctocogene roxaparvovec-rvox, per ml, containing nominal $2 \times 10^{13}$ vector genomes
Jan-24	<b>J1413</b>	Injection, delandistrogene moxeparvovec-rokl, per therapeutic dose
Jan-25	<b>J1414</b>	Injection, fidanacogene elaparvovec-dzkt, per therapeutic dose
Apr-24	<b>J1434</b>	Injection, fosaprepitant (focinvez), 1 mg
Jan-25	<b>J1552</b>	Injection, immune globulin (alyglo), 500 mg
Jan-24	<b>J1596</b>	Injection, glycopyrrolate, 0.1 mg
Jul-24	<b>J1597</b>	Injection, glycopyrrolate (glyrx-pf), 0.1 mg
Jul-24	<b>J1598</b>	Injection, glycopyrrolate (fresenius kabi), not therapeutically equivalent to j1596, 0.1 mg
Jul-24	<b>J1748</b>	Injection, infliximab-dyyb (zymfentra), 10 mg
Oct-24	<b>J1749</b>	Injection, iloprost, 0.1 mcg
Jan-24	<b>J1939</b>	Injection, bumetanide, 0.5 mg
Oct-24	<b>J2002</b>	Injection, lidocaine hcl in 5% dextrose, 1 mg
Oct-24	<b>J2003</b>	Injection, lidocaine hydrochloride, 1 mg
Oct-24	<b>J2004</b>	Injection, lidocaine hcl with epinephrine, 1 mg
Jul-24	<b>J2183</b>	Injection, meropenem (wg critical care), not therapeutically equivalent to j2185, 100 mg
Jul-24	<b>J2246</b>	Injection, micafungin in sodium (baxter), not therapeutically equivalent to j2248, 1 mg
Oct-24	<b>J2252</b>	Injection, midazolam in 0.8% sodium chloride, intravenous, not therapeutically equivalent to j2250, 1 mg
Oct-24	<b>J2253</b>	Injection, midazolam (seizalam), 1 mg
Jul-24	<b>J2267</b>	Injection, mirikizumab-mrkz, 1 mg
Apr-24	<b>J2277</b>	Injection, motixafortide, 0.25 mg
Jan-25	<b>J2290</b>	Injection, nafcillin sodium, 20 mg
Jul-24	<b>J2373</b>	Injection, phenylephrine hydrochloride (immphentiv), 20 micrograms
Jan-24	<b>J2404</b>	Injection, nicardipine, 0.1 mg
Jul-24	<b>J2468</b>	Injection, palonosetron hydrochloride (avyxa), not therapeutically equivalent to j2469, 25 micrograms
Jul-24	<b>J2470</b>	Injection, pantoprazole sodium, 40 mg
Jul-24	<b>J2471</b>	Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg
Jan-25	<b>J2472</b>	Injection, pantoprazole sodium in sodium chloride (baxter), 40 mg
Jan-24	<b>J2508</b>	Injection, pegunigalsidase alfa-iwxj, 1 mg
Oct-24	<b>J2601</b>	Injection, vasopressin (baxter), 1 unit
Jan-24	<b>J2679</b>	Injection, fluphenazine hcl, 1.25 mg
Apr-24	<b>J2782</b>	Injection, avacincaptad pegol, 0.1 mg
Jan-24	<b>J2799</b>	Injection, risperidone (uzedy), 1 mg
Apr-24	<b>J2801</b>	Injection, risperidone (rykindo), 0.5 mg
Jan-25	<b>J2802</b>	Injection, romiplostim, 1 microgram
Apr-24	<b>J2919</b>	Injection, methylprednisolone sodium succinate, 5 mg
Apr-24	<b>J3055</b>	Injection, talquetamab-tgvs, 0.25 mg
Jul-24	<b>J3247</b>	Injection, secukinumab, intravenous, 1 mg
Jul-24	<b>J3263</b>	Injection, toripalimab-tpzi, 1 mg
Jan-25	<b>J3392</b>	Injection, exagamglogene autotemcel, per treatment
Jul-24	<b>J3393</b>	Injection, betibeglogene autotemcel, per treatment
Jul-24	<b>J3394</b>	Injection, lovotibeglogene autotemcel, per treatment
Jan-24	<b>J3401</b>	Beremagene geperpavec-svdt for topical administration, containing nominal $5 \times 10^9$ pfu/ml vector genomes, per 0.1 ml

Apr-24	<b>J3424</b>	Injection, hydroxocobalamin, intravenous, 25 mg
Jan-24	<b>J3425</b>	Injection, hydroxocobalamin, 10 mcg
Apr-24	<b>J7165</b>	Injection, prothrombin complex concentrate, human-lans, per i.u. of factor ix activity
Jul-24	<b>J7171</b>	Injection, adams13, recombinant-krhn, 10 iu
Apr-24	<b>J7354</b>	Cantharidin for topical administration, 0.7%, single unit dose applicator (3.2 mg)
Jul-24	<b>J7355</b>	Injection, travoprost, intracameral implant, 1 microgram
Jan-25	<b>J7514</b>	Mycophenolate mofetil (myhibbin), oral suspension, 100 mg
Jan-25	<b>J7601</b>	Ensifentrine, inhalation suspension, fda approved final product, non-compounded, administered through dme, unit dose form, 3 mg
Oct-24	<b>J8522</b>	Capecitabine, oral, 50 mg
Oct-24	<b>J8541</b>	Dexamethasone (hemady), oral, 0.25 mg
Jul-24	<b>J8611</b>	Methotrexate (jylamvo), oral, 2.5 mg
Jul-24	<b>J8612</b>	Methotrexate (xatmep), oral, 2.5 mg
Jan-25	<b>J9026</b>	Injection, tarlatamab-dlle, 1 mg
Jan-25	<b>J9028</b>	Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram
Jan-24	<b>J9052</b>	Injection, carmustine (accord), not therapeutically equivalent to j9050, 100 mg
Jan-24	<b>J9072</b>	Injection, cyclophosphamide, (dr. reddy's), 5 mg
Apr-24	<b>J9073</b>	Injection, cyclophosphamide (ingenus), 5 mg
Apr-24	<b>J9074</b>	Injection, cyclophosphamide (sandoz), 5 mg
Apr-24	<b>J9075</b>	Injection, cyclophosphamide, not otherwise specified, 5 mg
Jan-25	<b>J9076</b>	Injection, cyclophosphamide (baxter), 5 mg
Jan-24	<b>J9172</b>	Injection, docetaxel (ingenus) not therapeutically equivalent to j9171, 1 mg
Apr-24	<b>J9248</b>	Injection, melphalan (hepato), 1 mg
Apr-24	<b>J9249</b>	Injection, melphalan (apotec), 1 mg
Jan-24	<b>J9255</b>	Injection, methotrexate (accord) not therapeutically equivalent to j9250 and j9260, 50 mg
Jan-24	<b>J9258</b>	Injection, paclitaxel protein-bound particles (teva) not therapeutically equivalent to j9264, 1 mg
Jan-24	<b>J9286</b>	Injection, glofitamab-gxbm, 2.5 mg
Jan-25	<b>J9292</b>	Injection, pemetrexed (avyxa), not therapeutically equivalent to j9305, 10 mg
Jan-24	<b>J9321</b>	Injection, epcoritamab-bysp, 0.16 mg
Jan-24	<b>J9324</b>	Injection, pemetrexed (pemrydi rtu), 10 mg
Oct-24	<b>J9329</b>	Injection, tislelizumab-jsgr, 1mg
Jan-24	<b>J9333</b>	Injection, rozanolixizumab-noli, 1 mg
Jan-24	<b>J9334</b>	Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc
Jul-24	<b>J9361</b>	Injection, efbemalenograstim alfa-vuxw, 0.5 mg
Apr-24	<b>J9376</b>	Injection, pozelimab-bbfg, 1 mg
Apr-24	<b>K1037</b>	Docking station for use with oral device/appliance used to reduce upper airway collapsibility
Oct-24	<b>L1006</b>	Scoliosis orthosis, sagittal-coronal control provided by a rigid lateral frame, extends from axilla to trochanter, includes all accessory pads, straps and interface, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise
Apr-24	<b>L1320</b>	Thoracic, pectus carinatum orthosis, sternal compression, rigid circumferential frame with anterior and posterior rigid pads, custom fabricated
Oct-24	<b>L1653</b>	Hip orthosis, bilateral thigh cuffs with adjustable abductor spreader bar, adult size, prefabricated, off the shelf
Oct-24	<b>L1821</b>	Knee orthosis, elastic with condylar pads and joints, with or without patellar control, prefabricated, off the shelf
Jan-24	<b>L3161</b>	Foot, adductus positioning device, adjustable
Jan-24	<b>L5615</b>	Addition, endoskeletal knee-shin system, 4 bar linkage or multiaxial, fluid swing and stance phase control
Apr-24	<b>L5783</b>	Addition to lower extremity, user adjustable, mechanical, residual limb volume management system
Apr-24	<b>L5841</b>	Addition, endoskeletal knee-shin system, polycentric, pneumatic swing, and stance phase control
Jan-24	<b>L5926</b>	Addition to lower extremity prosthesis, endoskeletal, knee disarticulation, above knee, hip disarticulation, positional rotation unit, any type
Oct-24	<b>L8720</b>	External lower extremity sensory prosthesis, cutaneous stimulation of mechanoreceptors proximal to the ankle, per leg
Oct-24	<b>L8721</b>	Receptor sole for use with l8720, replacement, each
Oct-24	<b>P9027</b>	Red blood cells, leukocytes reduced, oxygen/ carbon dioxide reduced, each unit
Jan-25	<b>Q0155</b>	Dronabinol (syndros), 0.1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
Apr-24	<b>Q0224</b>	Injection, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, and who either have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments, and are unlikely to mount an adequate immune response to covid-19 vaccination, 4500 mg
Jul-24	<b>Q0224</b>	Injection, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, and who either have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments, and are unlikely to mount an adequate immune response to covid-19 vaccination, 4500 mg

Jan-24	<b>Q0516</b>	Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription drug, per 30-days
Jan-24	<b>Q0517</b>	Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription drug, per 60-days
Jan-24	<b>Q0518</b>	Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription drug, per 90-days
Oct-24	<b>Q0519</b>	Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription injectable drug, per 30-days
Oct-24	<b>Q0520</b>	Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription injectable drug, per 60-days
Jan-25	<b>Q0521</b>	Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription
Jan-24	<b>Q4279</b>	Vendaje ac, per square centimeter
Jan-24	<b>Q4287</b>	Dermabind dl, per square centimeter
Jan-24	<b>Q4288</b>	Dermabind ch, per square centimeter
Jan-24	<b>Q4289</b>	Revoshield + amniotic barrier, per square centimeter
Jan-24	<b>Q4290</b>	Membrane wrap-hydro, per square centimeter
Jan-24	<b>Q4291</b>	Lamellas xt, per square centimeter
Jan-24	<b>Q4292</b>	Lamellas, per square centimeter
Jan-24	<b>Q4293</b>	Acesso dl, per square centimeter
Jan-24	<b>Q4294</b>	Amnio quad-core, per square centimeter
Jan-24	<b>Q4295</b>	Amnio tri-core amniotic, per square centimeter
Jan-24	<b>Q4296</b>	Rebound matrix, per square centimeter
Jan-24	<b>Q4297</b>	Emerge matrix, per square centimeter
Jan-24	<b>Q4298</b>	Amnicore pro, per square centimeter
Jan-24	<b>Q4299</b>	Amnicore pro+, per square centimeter
Jan-24	<b>Q4300</b>	Acesso tl, per square centimeter
Jan-24	<b>Q4301</b>	Activate matrix, per square centimeter
Jan-24	<b>Q4302</b>	Complete aca, per square centimeter
Jan-24	<b>Q4303</b>	Complete aa, per square centimeter
Jan-24	<b>Q4304</b>	Grafix plus, per square centimeter
Apr-24	<b>Q4305</b>	American amnion ac tri-layer, per square centimeter
Apr-24	<b>Q4306</b>	American amnion ac, per square centimeter
Apr-24	<b>Q4307</b>	American amnion, per square centimeter
Apr-24	<b>Q4308</b>	Sanopellis, per square centimeter
Apr-24	<b>Q4309</b>	Via matrix, per square centimeter
Apr-24	<b>Q4310</b>	Procenta, per 100 mg
Jul-24	<b>Q4311</b>	Acesso, per square centimeter
Jul-24	<b>Q4312</b>	Acesso ac, per square centimeter
Jul-24	<b>Q4313</b>	Dermabind fm, per square centimeter
Jul-24	<b>Q4314</b>	Reeva ft, per square centimeter
Jul-24	<b>Q4315</b>	Regenelink amniotic membrane allograft, per square centimeter
Jul-24	<b>Q4316</b>	Amchoplast, per square centimeter
Jul-24	<b>Q4317</b>	Vitograft, per square centimeter
Jul-24	<b>Q4318</b>	E-graft, per square centimeter
Jul-24	<b>Q4319</b>	Sanograft, per square centimeter
Jul-24	<b>Q4320</b>	Pellograft, per square centimeter
Jul-24	<b>Q4321</b>	Renograft, per square centimeter
Jul-24	<b>Q4322</b>	Caregraft, per square centimeter
Jul-24	<b>Q4323</b>	Alloply, per square centimeter
Jul-24	<b>Q4324</b>	Amniotx, per square centimeter
Jul-24	<b>Q4325</b>	Acapatch, per square centimeter
Jul-24	<b>Q4326</b>	Woundplus, per square centimeter
Jul-24	<b>Q4327</b>	Duoamnion, per square centimeter
Jul-24	<b>Q4328</b>	Most, per square centimeter
Jul-24	<b>Q4329</b>	Singlay, per square centimeter
Jul-24	<b>Q4330</b>	Total, per square centimeter
Jul-24	<b>Q4331</b>	Axolotl graft, per square centimeter
Jul-24	<b>Q4332</b>	Axolotl dualgraft, per square centimeter
Jul-24	<b>Q4333</b>	Ardeograft, per square centimeter
Oct-24	<b>Q4334</b>	Amnioplast 1, per square centimeter
Oct-24	<b>Q4335</b>	Amnioplast 2, per square centimeter
Oct-24	<b>Q4336</b>	Artacent c, per square centimeter
Oct-24	<b>Q4337</b>	Artacent trident, per square centimeter
Oct-24	<b>Q4338</b>	Artacent velos, per square centimeter



Oct-24	<b>Q4339</b>	Artacent vericlen, per square centimeter
Oct-24	<b>Q4340</b>	Simpligraft, per square centimeter
Oct-24	<b>Q4341</b>	Simplimax, per square centimeter
Oct-24	<b>Q4342</b>	Theramend, per square centimeter
Oct-24	<b>Q4343</b>	Dermacyte ac matrix amniotic membrane allograft, per square centimeter
Oct-24	<b>Q4344</b>	Tri-membrane wrap, per square centimeter
Oct-24	<b>Q4345</b>	Matrix hd allograft dermis, per square centimeter
Jan-25	<b>Q4346</b>	Shelter dm matrix, per square centimeter
Jan-25	<b>Q4347</b>	Rampart dl matrix, per square centimeter
Jan-25	<b>Q4348</b>	Sentry sl matrix, per square centimeter
Jan-25	<b>Q4349</b>	Mantle dl matrix, per square centimeter
Jan-25	<b>Q4350</b>	Palisade dm matrix, per square centimeter
Jan-25	<b>Q4351</b>	Enclose tl matrix, per square centimeter
Jan-25	<b>Q4352</b>	Overlay sl matrix, per square centimeter
Jan-25	<b>Q4353</b>	Xceed tl matrix, per square centimeter
Jan-24	<b>Q5132</b>	Injection, adalimumab-afzb (abrilada), biosimilar, 10 mg
Apr-24	<b>Q5133</b>	Injection, tocilizumab-bavi (tofidence), biosimilar, 1 mg
Apr-24	<b>Q5134</b>	Injection, natalizumab-sztn (tyruko), biosimilar, 1 mg
Oct-24	<b>Q5135</b>	Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg
Oct-24	<b>Q5136</b>	Injection, denosumab-bbdz (jubboniti/wyost), biosimilar, 1 mg
Jul-24	<b>Q5137</b>	Injection, ustekinumab-auub (wezłana), biosimilar, subcutaneous, 1 mg
Jul-24	<b>Q5138</b>	Injection, ustekinumab-auub (wezłana), biosimilar, intravenous, 1 mg
Jan-25	<b>Q5139</b>	Injection, eculizumab-aeeb (bkernv), biosimilar, 10 mg
Jan-25	<b>Q5140</b>	Injection, adalimumab-fkjp, biosimilar, 1 mg
Jan-25	<b>Q5141</b>	Injection, adalimumab-aaty, biosimilar, 1 mg
Jan-25	<b>Q5142</b>	Injection, adalimumab-ryvk biosimilar, 1 mg
Jan-25	<b>Q5143</b>	Injection, adalimumab-adbm, biosimilar, 1 mg
Jan-25	<b>Q5144</b>	Injection, adalimumab-aacf (idacio), biosimilar, 1 mg
Jan-25	<b>Q5145</b>	Injection, adalimumab-afzb (abrilada), biosimilar, 1 mg
Jan-25	<b>Q5146</b>	Injection, trastuzumab-strf (hercessi), biosimilar, 10 mg
Jan-25	<b>Q9996</b>	Injection, ustekinumab-ttwe (pyzchiva), subcutaneous, 1 mg
Jan-25	<b>Q9997</b>	Injection, ustekinumab-ttwe (pyzchiva), intravenous, 1 mg
Jan-25	<b>Q9998</b>	Injection, ustekinumab-aekn (selarsdi), 1 mg
Apr-24	<b>S4988</b>	Penile contracture device, manual, greater than 3 lbs traction force
Apr-24	<b>S9002</b>	Intra-vaginal motion sensor system, provides biofeedback for pelvic floor muscle rehabilitation device